US20240035097A1 - Detection of bacterial infections - Google Patents
Detection of bacterial infections Download PDFInfo
- Publication number
- US20240035097A1 US20240035097A1 US18/111,996 US202318111996A US2024035097A1 US 20240035097 A1 US20240035097 A1 US 20240035097A1 US 202318111996 A US202318111996 A US 202318111996A US 2024035097 A1 US2024035097 A1 US 2024035097A1
- Authority
- US
- United States
- Prior art keywords
- bacterial
- infection
- subject
- gene
- dusp1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000035143 Bacterial infection Diseases 0.000 title claims abstract description 172
- 208000022362 bacterial infectious disease Diseases 0.000 title claims abstract description 171
- 238000001514 detection method Methods 0.000 title description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 156
- 238000000034 method Methods 0.000 claims abstract description 155
- 208000015181 infectious disease Diseases 0.000 claims abstract description 134
- 230000014509 gene expression Effects 0.000 claims abstract description 106
- 102100034428 Dual specificity protein phosphatase 1 Human genes 0.000 claims abstract description 53
- 101000924017 Homo sapiens Dual specificity protein phosphatase 1 Proteins 0.000 claims abstract description 53
- 101000881110 Homo sapiens Dual specificity protein phosphatase 12 Proteins 0.000 claims abstract description 52
- 101000840275 Homo sapiens Interferon alpha-inducible protein 27, mitochondrial Proteins 0.000 claims abstract description 42
- 102100029604 Interferon alpha-inducible protein 27, mitochondrial Human genes 0.000 claims abstract description 42
- 210000002345 respiratory system Anatomy 0.000 claims abstract description 37
- 101000868472 Homo sapiens Sialoadhesin Proteins 0.000 claims description 29
- 102100032855 Sialoadhesin Human genes 0.000 claims description 29
- 101000959664 Homo sapiens Interferon-induced protein 44-like Proteins 0.000 claims description 28
- 102100039953 Interferon-induced protein 44-like Human genes 0.000 claims description 27
- 241000894006 Bacteria Species 0.000 claims description 25
- 239000003242 anti bacterial agent Substances 0.000 claims description 25
- 244000052769 pathogen Species 0.000 claims description 24
- 210000004369 blood Anatomy 0.000 claims description 20
- 239000008280 blood Substances 0.000 claims description 20
- 241000588724 Escherichia coli Species 0.000 claims description 19
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 18
- 208000011580 syndromic disease Diseases 0.000 claims description 17
- 206010035664 Pneumonia Diseases 0.000 claims description 16
- 241000191967 Staphylococcus aureus Species 0.000 claims description 15
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 13
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 13
- 241000606768 Haemophilus influenzae Species 0.000 claims description 12
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 12
- 208000007764 Legionnaires' Disease Diseases 0.000 claims description 11
- 206010040047 Sepsis Diseases 0.000 claims description 11
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 11
- 201000009906 Meningitis Diseases 0.000 claims description 8
- 241000588655 Moraxella catarrhalis Species 0.000 claims description 8
- 241000202934 Mycoplasma pneumoniae Species 0.000 claims description 8
- 241000588650 Neisseria meningitidis Species 0.000 claims description 8
- 241000193985 Streptococcus agalactiae Species 0.000 claims description 8
- 210000001124 body fluid Anatomy 0.000 claims description 8
- 239000010839 body fluid Substances 0.000 claims description 8
- 238000002493 microarray Methods 0.000 claims description 8
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 7
- 241000589875 Campylobacter jejuni Species 0.000 claims description 6
- 241000606161 Chlamydia Species 0.000 claims description 6
- 241001647372 Chlamydia pneumoniae Species 0.000 claims description 6
- 238000003757 reverse transcription PCR Methods 0.000 claims description 6
- 241000588626 Acinetobacter baumannii Species 0.000 claims description 5
- 241000186779 Listeria monocytogenes Species 0.000 claims description 5
- 102100023809 Adipocyte plasma membrane-associated protein Human genes 0.000 claims description 4
- 101000684373 Homo sapiens Adipocyte plasma membrane-associated protein Proteins 0.000 claims description 4
- 101000578329 Homo sapiens Glycylpeptide N-tetradecanoyltransferase 1 Proteins 0.000 claims description 4
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 4
- 238000003559 RNA-seq method Methods 0.000 claims description 4
- 201000008827 tuberculosis Diseases 0.000 claims description 4
- 102100025975 Cathepsin G Human genes 0.000 claims description 3
- 241001445332 Coxiella <snail> Species 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims description 3
- 206010061166 Gastroenteritis bacterial Diseases 0.000 claims description 3
- 102100028085 Glycylpeptide N-tetradecanoyltransferase 1 Human genes 0.000 claims description 3
- 101000933179 Homo sapiens Cathepsin G Proteins 0.000 claims description 3
- 101000653759 Homo sapiens Sphingosine 1-phosphate receptor 5 Proteins 0.000 claims description 3
- 241000588653 Neisseria Species 0.000 claims description 3
- 201000005702 Pertussis Diseases 0.000 claims description 3
- 102100029802 Sphingosine 1-phosphate receptor 5 Human genes 0.000 claims description 3
- 210000001179 synovial fluid Anatomy 0.000 claims description 3
- 102100024581 Alpha-taxilin Human genes 0.000 claims description 2
- 241000186216 Corynebacterium Species 0.000 claims description 2
- 102100034893 E3 ubiquitin-protein ligase HUWE1 Human genes 0.000 claims description 2
- 102100023686 G protein-coupled receptor kinase 6 Human genes 0.000 claims description 2
- 102100037848 Heterochromatin protein 1-binding protein 3 Human genes 0.000 claims description 2
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 claims description 2
- 101000760787 Homo sapiens Alpha-taxilin Proteins 0.000 claims description 2
- 101001019732 Homo sapiens E3 ubiquitin-protein ligase HUWE1 Proteins 0.000 claims description 2
- 101000847538 Homo sapiens Flotillin-1 Proteins 0.000 claims description 2
- 101000829473 Homo sapiens G protein-coupled receptor kinase 6 Proteins 0.000 claims description 2
- 101001025546 Homo sapiens Heterochromatin protein 1-binding protein 3 Proteins 0.000 claims description 2
- 101001045846 Homo sapiens Histone-lysine N-methyltransferase 2A Proteins 0.000 claims description 2
- 238000000636 Northern blotting Methods 0.000 claims description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 2
- 241001147691 Staphylococcus saprophyticus Species 0.000 claims description 2
- 238000001114 immunoprecipitation Methods 0.000 claims description 2
- 238000004949 mass spectrometry Methods 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 238000003127 radioimmunoassay Methods 0.000 claims description 2
- 238000003753 real-time PCR Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 102100029753 Reduced folate transporter Human genes 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 abstract description 80
- 238000011282 treatment Methods 0.000 abstract description 55
- 238000012544 monitoring process Methods 0.000 abstract description 9
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 3
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- 239000000523 sample Substances 0.000 description 92
- 230000035945 sensitivity Effects 0.000 description 29
- 102100033174 Neutrophil elastase Human genes 0.000 description 24
- 238000012360 testing method Methods 0.000 description 24
- 239000003550 marker Substances 0.000 description 20
- 230000003612 virological effect Effects 0.000 description 19
- 230000004044 response Effects 0.000 description 18
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 12
- 229940088710 antibiotic agent Drugs 0.000 description 12
- 230000003115 biocidal effect Effects 0.000 description 12
- 208000036142 Viral infection Diseases 0.000 description 11
- 230000001717 pathogenic effect Effects 0.000 description 11
- 230000009385 viral infection Effects 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 244000052616 bacterial pathogen Species 0.000 description 10
- 229940045505 klebsiella pneumoniae Drugs 0.000 description 9
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 8
- 238000004364 calculation method Methods 0.000 description 8
- 206010022000 influenza Diseases 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 208000031729 Bacteremia Diseases 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 238000002405 diagnostic procedure Methods 0.000 description 7
- -1 fluoroquinolone Chemical compound 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 5
- 206010027202 Meningitis bacterial Diseases 0.000 description 5
- 201000009904 bacterial meningitis Diseases 0.000 description 5
- 229960004755 ceftriaxone Drugs 0.000 description 5
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 201000004792 malaria Diseases 0.000 description 5
- 229960002260 meropenem Drugs 0.000 description 5
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 5
- 239000013610 patient sample Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229930186147 Cephalosporin Natural products 0.000 description 4
- 241001500351 Influenzavirus A Species 0.000 description 4
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- 229940124587 cephalosporin Drugs 0.000 description 4
- 150000001780 cephalosporins Chemical class 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229940124307 fluoroquinolone Drugs 0.000 description 4
- 208000037797 influenza A Diseases 0.000 description 4
- 229940056360 penicillin g Drugs 0.000 description 4
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 3
- 241001647378 Chlamydia psittaci Species 0.000 description 3
- 241000223205 Coccidioides immitis Species 0.000 description 3
- 208000003322 Coinfection Diseases 0.000 description 3
- 241000711573 Coronaviridae Species 0.000 description 3
- 241000709687 Coxsackievirus Species 0.000 description 3
- 201000007336 Cryptococcosis Diseases 0.000 description 3
- 241000221204 Cryptococcus neoformans Species 0.000 description 3
- 241000673115 Cryptosporidium hominis Species 0.000 description 3
- 241000223936 Cryptosporidium parvum Species 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 241001466953 Echovirus Species 0.000 description 3
- 241000589602 Francisella tularensis Species 0.000 description 3
- 241000228404 Histoplasma capsulatum Species 0.000 description 3
- 241000701096 Human adenovirus 7 Species 0.000 description 3
- 241001135572 Human adenovirus E4 Species 0.000 description 3
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 241000701027 Human herpesvirus 6 Species 0.000 description 3
- 241000342334 Human metapneumovirus Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001500350 Influenzavirus B Species 0.000 description 3
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 3
- 241000150452 Orthohantavirus Species 0.000 description 3
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 3
- 206010037596 Pyelonephritis Diseases 0.000 description 3
- 241000725643 Respiratory syncytial virus Species 0.000 description 3
- 241001113283 Respirovirus Species 0.000 description 3
- 241001533467 Rubulavirus Species 0.000 description 3
- 241000607764 Shigella dysenteriae Species 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 229940126575 aminoglycoside Drugs 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000009640 blood culture Methods 0.000 description 3
- 229940047766 co-trimoxazole Drugs 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 229940118764 francisella tularensis Drugs 0.000 description 3
- 229940047650 haemophilus influenzae Drugs 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 208000037798 influenza B Diseases 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 229940007046 shigella dysenteriae Drugs 0.000 description 3
- 208000019206 urinary tract infection Diseases 0.000 description 3
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 2
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 2
- 241000606678 Coxiella burnetii Species 0.000 description 2
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 208000002476 Falciparum Malaria Diseases 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 244000309467 Human Coronavirus Species 0.000 description 2
- 241000598171 Human adenovirus sp. Species 0.000 description 2
- 241000711920 Human orthopneumovirus Species 0.000 description 2
- 241000430519 Human rhinovirus sp. Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 101710188663 Non-structural protein 5a Proteins 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 2
- 208000035109 Pneumococcal Infections Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241001138501 Salmonella enterica Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000003096 antiparasitic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960003644 aztreonam Drugs 0.000 description 2
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 229960002100 cefepime Drugs 0.000 description 2
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 2
- 229960004261 cefotaxime Drugs 0.000 description 2
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229940041007 third-generation cephalosporins Drugs 0.000 description 2
- ZMYFCFLJBGAQRS-IRXDYDNUSA-N (2R,3S)-epoxiconazole Chemical compound C1=CC(F)=CC=C1[C@@]1(CN2N=CN=C2)[C@H](C=2C(=CC=CC=2)Cl)O1 ZMYFCFLJBGAQRS-IRXDYDNUSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 1
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 description 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
- JGPNCLKRECLYTO-BJMVGYQFSA-N 1-ethyl-1-[(e)-(5-nitrofuran-2-yl)methylideneamino]urea Chemical compound CCN(C(N)=O)\N=C\C1=CC=C([N+]([O-])=O)O1 JGPNCLKRECLYTO-BJMVGYQFSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- JLGKQTAYUIMGRK-UHFFFAOYSA-N 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 JLGKQTAYUIMGRK-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- KMJWBVJQFGRCEB-UHFFFAOYSA-O 4-n-(4-imino-1,2-dimethylquinolin-6-yl)-1,6-dimethylpyrimidin-1-ium-2,4-diamine Chemical compound C=1C=C2N(C)C(C)=CC(=N)C2=CC=1NC1=CC(C)=[N+](C)C(N)=N1 KMJWBVJQFGRCEB-UHFFFAOYSA-O 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 241000186041 Actinomyces israelii Species 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 108010064760 Anidulafungin Proteins 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 108700003860 Bacterial Genes Proteins 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 241001518086 Bartonella henselae Species 0.000 description 1
- 241000606108 Bartonella quintana Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000180135 Borrelia recurrentis Species 0.000 description 1
- 241001148604 Borreliella afzelii Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241001148605 Borreliella garinii Species 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 241000589567 Brucella abortus Species 0.000 description 1
- 241001509299 Brucella canis Species 0.000 description 1
- 241001148106 Brucella melitensis Species 0.000 description 1
- 241001148111 Brucella suis Species 0.000 description 1
- 108010020326 Caspofungin Proteins 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- 229940122444 Chemokine receptor antagonist Drugs 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000605312 Ehrlichia canis Species 0.000 description 1
- 241000605310 Ehrlichia chaffeensis Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 239000005767 Epoxiconazole Substances 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 102100032790 Flotillin-1 Human genes 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000006968 Helminthiasis Diseases 0.000 description 1
- 206010020429 Human ehrlichiosis Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 241000589929 Leptospira interrogans Species 0.000 description 1
- 241001135196 Leptospira noguchii Species 0.000 description 1
- 241001135198 Leptospira santarosai Species 0.000 description 1
- 241001135200 Leptospira weilii Species 0.000 description 1
- YTAOBBFIOAEMLL-REQDGWNSSA-N Luliconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@H](CS\1)SC/1=C(\C#N)N1C=NC=C1 YTAOBBFIOAEMLL-REQDGWNSSA-N 0.000 description 1
- IPWKIXLWTCNBKN-UHFFFAOYSA-N Madelen Chemical compound CC1=NC=C([N+]([O-])=O)N1CC(O)CCl IPWKIXLWTCNBKN-UHFFFAOYSA-N 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- JCYZMTMYPZHVBF-UHFFFAOYSA-N Melarsoprol Chemical compound NC1=NC(N)=NC(NC=2C=CC(=CC=2)[As]2SC(CO)CS2)=N1 JCYZMTMYPZHVBF-UHFFFAOYSA-N 0.000 description 1
- 108010021062 Micafungin Proteins 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 229940123424 Neuraminidase inhibitor Drugs 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 241001432884 Orthopneumovirus Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000005822 Propiconazole Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 206010037151 Psittacosis Diseases 0.000 description 1
- 206010037688 Q fever Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- 241000202921 Ureaplasma urealyticum Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 241000607477 Yersinia pseudotuberculosis Species 0.000 description 1
- TYBHXIFFPVFXQW-UHFFFAOYSA-N abafungin Chemical compound CC1=CC(C)=CC=C1OC1=CC=CC=C1C1=CSC(NC=2NCCCN=2)=N1 TYBHXIFFPVFXQW-UHFFFAOYSA-N 0.000 description 1
- 229950006373 abafungin Drugs 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- UHIXWHUVLCAJQL-MPBGBICISA-N albaconazole Chemical compound C([C@@](O)([C@H](N1C(C2=CC=C(Cl)C=C2N=C1)=O)C)C=1C(=CC(F)=CC=1)F)N1C=NC=N1 UHIXWHUVLCAJQL-MPBGBICISA-N 0.000 description 1
- 229950006816 albaconazole Drugs 0.000 description 1
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 1
- 229960002669 albendazole Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229960003348 anidulafungin Drugs 0.000 description 1
- JHVAMHSQVVQIOT-MFAJLEFUSA-N anidulafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@@H](C)O)[C@H](O)[C@@H](O)C=2C=CC(O)=CC=2)[C@@H](C)O)=O)C=C1 JHVAMHSQVVQIOT-MFAJLEFUSA-N 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000884 anti-protozoa Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 229960000981 artemether Drugs 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 229940092524 bartonella henselae Drugs 0.000 description 1
- 229940092523 bartonella quintana Drugs 0.000 description 1
- 229960002206 bifonazole Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940056450 brucella abortus Drugs 0.000 description 1
- 229940038698 brucella melitensis Drugs 0.000 description 1
- 229960005074 butoconazole Drugs 0.000 description 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 1
- 229960003034 caspofungin Drugs 0.000 description 1
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000002559 chemokine receptor antagonist Substances 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960003937 efinaconazole Drugs 0.000 description 1
- NFEZZTICAUWDHU-RDTXWAMCSA-N efinaconazole Chemical compound N1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)CCC(=C)CC1 NFEZZTICAUWDHU-RDTXWAMCSA-N 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- 229940051998 ehrlichia canis Drugs 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 229960001274 fenticonazole Drugs 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940124525 integrase strand transfer inhibitor Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960000788 isavuconazole Drugs 0.000 description 1
- DDFOUSQFMYRUQK-RCDICMHDSA-N isavuconazole Chemical compound C=1SC([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC=C(F)C=2)F)=NC=1C1=CC=C(C#N)C=C1 DDFOUSQFMYRUQK-RCDICMHDSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 238000013150 knee replacement Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 229960000570 luliconazole Drugs 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 229960003439 mebendazole Drugs 0.000 description 1
- BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 description 1
- 229960001728 melarsoprol Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960002159 micafungin Drugs 0.000 description 1
- PIEUQSKUWLMALL-YABMTYFHSA-N micafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@H](O)CC(N)=O)[C@H](O)[C@@H](O)C=2C=C(OS(O)(=O)=O)C(O)=CC=2)[C@@H](C)O)=O)=NO1 PIEUQSKUWLMALL-YABMTYFHSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
- 229950007888 nifursemizone Drugs 0.000 description 1
- 229960002480 nitazoxanide Drugs 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 229960004031 omoconazole Drugs 0.000 description 1
- JMFOSJNGKJCTMJ-ZHZULCJRSA-N omoconazole Chemical compound C1=CN=CN1C(/C)=C(C=1C(=CC(Cl)=CC=1)Cl)\OCCOC1=CC=C(Cl)C=C1 JMFOSJNGKJCTMJ-ZHZULCJRSA-N 0.000 description 1
- 229960002313 ornidazole Drugs 0.000 description 1
- 201000000901 ornithosis Diseases 0.000 description 1
- 229960003483 oxiconazole Drugs 0.000 description 1
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 1
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- STJLVHWMYQXCPB-UHFFFAOYSA-N propiconazole Chemical compound O1C(CCC)COC1(C=1C(=CC(Cl)=CC=1)Cl)CN1N=CN=C1 STJLVHWMYQXCPB-UHFFFAOYSA-N 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- 229960000611 pyrimethamine Drugs 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- OPAHEYNNJWPQPX-RCDICMHDSA-N ravuconazole Chemical compound C=1SC([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=1C1=CC=C(C#N)C=C1 OPAHEYNNJWPQPX-RCDICMHDSA-N 0.000 description 1
- 229950004154 ravuconazole Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 229960005429 sertaconazole Drugs 0.000 description 1
- 229940115939 shigella sonnei Drugs 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 229960002607 sulconazole Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960000580 terconazole Drugs 0.000 description 1
- 229960005053 tinidazole Drugs 0.000 description 1
- 229960004214 tioconazole Drugs 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 208000037972 tropical disease Diseases 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6893—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Definitions
- the present invention relates to methods of detecting an infection in a subject.
- the invention also relates to methods of detecting a bacterial infection and methods of detecting a non-bacterial infection in a subject.
- the present invention also relates to a method of distinguishing between a bacterial infection or a non-bacterial infection in a subject, especially between bacterial and non-bacterial lower respiratory system infection.
- the invention provides the medical use of therapeutic agents in the treatment of a bacterial or non-bacterial infection in a subject identified as having such an infection through use of a method of the invention.
- the invention also relates to a method of treating an infection in a subject, and a method of detecting relative abundance of target molecules in a subject suspected of having or developing an infection.
- Infections both bacterial and non-bacterial are a significant cause of morbidity and mortality in UK and worldwide. Infections can involve body compartments, organs or indeed the whole body. If left undiagnosed and untreated, infections can lead to sepsis, disability and sometimes loss of life.
- the invention relates to a method of detecting an infection in a subject, the method comprising:
- the invention relates to method of detecting a bacterial infection in a subject, the method comprising:
- the invention relates to a method of detecting a non-bacterial infection in a subject, the method comprising:
- the invention relates to a method of distinguishing between a bacterial infection and a non-bacterial infection in a subject, the method comprising:
- the invention relates to a method of determining the cause of an infection in a subject, the method comprising:
- the invention relates to an antibacterial agent for use in the treatment of a bacterial infection in a subject identified as having a bacterial infection by a method according to first, second, fourth and fifth aspect.
- the invention relates to a therapeutic agent for use in the treatment of a non-bacterial infection in a subject identified as having a non-bacterial infection by a method according to a first, third, fourth and fifth aspect.
- a method of the first aspect, in which an infection is detected in a subject may further comprise a step of providing the subject with treatment for the pathogen-associated infection.
- the invention relates to a method of treating an infection in a subject, the method comprising:
- the invention relates to a method of detecting the relative abundance of target molecules in a subject suspected of having or developing an infection, the method comprising:
- the invention relates to a method of monitoring the therapeutic effectiveness of a treatment for a subject having an infection, the method comprising:
- a method of detecting an infection in a subject in accordance with the first aspect of the invention, or a method of detecting a bacterial infection in a subject in accordance with the second aspect of the invention, in which a bacterial infection is detected in a subject may further comprise a step of conducting a further confirmatory test for the bacterial infection in the subject.
- a bacterial infection is diagnosed when the results of both the first test (a method of the first and/or second aspect of the invention) and the second test (the confirmatory test) indicate the presence of bacterial infection.
- a sample of biological fluid such as CSF from lumbar puncture or blood from venepuncture, may be cultured in order to grow the microorganism associated with infection. This allows confirmation of bacterial infection and also allows determination of antimicrobial susceptibility of any isolated pathogen.
- a method of detecting a non-bacterial infection in a subject may further comprise a step of conducting a further confirmatory test for the non-bacterial infection in the subject.
- a non-bacterial infection is diagnosed when the results of both the first test (a method of the first and/or second aspect of the invention) and the second test (the confirmatory test) indicate the presence of non-bacterial infection.
- a sample of biological fluid such as a sputum or blood, may be tested for the presence of DNA from a non-bacterial pathogen (such as a virus or parasite). This allows confirmation of non-bacterial infection and also allows determination of appropriate treatment.
- Methods in accordance with the first, second, third, fourth, fifth, eighth ninth, or tenth aspects of the invention may comprise obtaining data indicative of the relative abundance of target molecules indicative of the expression a further gene pair.
- further gene pairs particularly suitable for use in embodiments of the methods of invention may include at least one of: DUSP1 and SIGLEC1; ELANE and IFI27; DUSP1 and IFI44L; ELANE and SIGLEC1; or ELANE and IFI44L.
- references to the methods of the invention may be taken as encompassing the detecting methods of the first, second, third or ninth aspects of the invention, or methods of distinguishing between bacterial infection and non-bacterial infection of the fourth aspect, or method of determining the cause of infection according to the fifth aspect, or method of treating according to the eight aspect (and therefore the medical uses of the sixth or seventh aspects), or method of monitoring according to the tenth aspect.
- the methods of the present invention provide simple tests that may be used for diagnosing infections, in particular for diagnosing and distinguishing between bacterial or non-bacterial infections.
- infections include, but are not limited to, lower respiratory tract infections, meningitis, and tropical diseases, for example malaria. Other examples of infections are discussed elsewhere in this specification.
- the methods of the invention are advantageous, because they may allow a swifter identification of patients with suspected bacterial infections, which in turn, allows medical staff to commence appropriate treatment promptly, as well as prevent patients with non-bacterial infections from receiving unnecessary antibiotics. This advantageously reduces the problem of antibiotic resistance among pathogenic bacteria. Moreover, the inventors have surprisingly found that the methods of the invention diagnose and distinguish between bacterial and non-bacterial infections with a very high degree of sensitivity and specificity.
- the methods of the present invention may allow the detection of bacterial infections, such as lower respiratory tract infections, even in cases where the sample is collected after the patients has already received antibiotics and/or other anti-microbial treatment. This is in contrast to conventional methods for detecting bacteria, such as bacterial culture, which often show poor sensitivity (fail to detect true cases of bacterial infection) when patient samples are collected after anti-microbial treatment has been initiated.
- the methods of the present invention may reduce the risk of missing true cases of bacterial infections among patients who have previously begun treatment with antibiotics.
- the methods of the present invention can be used to detect infections remote from the source of the infection.
- the methods rely on the detection of the expression of one or more gene pairs that can be detected in any sample such as a blood sample, without requiring a sample to be taken from where the infection may be present.
- a CNS infection may be detected from a blood sample rather than requiring a cerebrospinal fluid (CSF) sample to be taken.
- CSF cerebrospinal fluid
- the methods of the present invention are based on the inventors' selection of a specific gene pair, or combination of gene pairs, which allow(s) the detection of an infection, such as a bacterial or non-bacterial infection, as well as the distinction between a bacterial and non-bacterial infection.
- FIG. 1 Microarray data showing gene expression in community acquired pneumonia (CAP) patient samples from the UK via Agilent gene-expression micro-arrays (11 proven bacterial pneumonia, and six proven viral [influenza] pneumonia [bacteria proven by culture in blood and influenza proven by PCR on nasopharyngeal swab]). Based on relative transcript abundance (red (dark areas)—high abundance/green (light areas)—low abundance) across the samples, 87 transcripts were significantly (false detection rate ⁇ 5% [p ⁇ 0.05]) differentially expressed among the group of proven bacterial CAP compared to others; a sub-set of transcripts exhibiting differential abundance are shown in FIG. 1 .
- This data provided proof of principle that pairs of markers exhibiting reciprocal changes in expression between bacterial infections like bacterial CAP and viral infection mimics exist.
- FIG. 2 A. Plot of expression ratio (Y-axis) for the six top scoring pairs of genes, from left to right: D/I-DUSP1/IFI27 [1]; E/I-ELANE/IFI27 [2]; D/S-DUSP1/SIGLEC1 [3]; E/S-ELANE/SIGLEC1 [4]; E/44-ELANE/IFI44L [5]; D/44-DUSP1/IFI44L [6]; measured via RT-PCR.
- the dotted horizontal line represents the predetermined threshold for the relative abundance expression ratio for classifying a sample as having a bacterial infection
- Each dot on the x-axis represents a sample.
- a different coloured/shaped dot on the y-axis corresponds to the same sample measured by a different gene pair.
- X-axis corresponds to the number of days the patient had been treated with antibiotics prior to sampling.
- infection refers the undesired presence and/or growth of a pathogen in a subject that has a negative effect on the subject's health and/or well-being. While the term “infection” should not be taken as encompassing the growth and/or presence of pathogens, such as bacteria, which are normally present in the subject (for example in the digestive tract of the subject), it may encompass the pathological overgrowth of such bacteria.
- pathogens such as bacteria
- An infection may involve any body compartment. Accordingly, methods or medical uses of the present invention are applicable to infection in any system, organ or area of the subject, such as, but not limited to, lower respiratory system, upper respiratory system, central nervous system, gastrointestinal system, urinary system, the ocular system, the auditory system, and/or the skin.
- the infection can also involve multiple body compartments, or in fact the whole body. Accordingly, methods and medical uses of the present invention are applicable to diseases such as bacteraemia, septicaemia, sepsis, Epstein-Barr virus infection, malaria, and helminthiasis.
- the infection is a pathogen-associated infection.
- the infection may be bacterial or non-bacterial. Such an embodiment gives rise to the second and third aspects of the invention.
- the infection can be a combined bacterial and non-bacterial infection.
- a bacterial infection may arise as a secondary infection due to a non-bacterial infection (such as a viral infection).
- a non-bacterial infection is selected from the group consisting of a viral, a parasitic, a protozoan and a fungal infection. More suitably, a non-bacterial infection is a viral or a parasitic infection. Examples of bacterial or non-bacterial infections are discussed hereinbelow.
- a “bacterial infection” is an infection caused by the undesired presence and/or growth of bacteria in a subject.
- bacterial infections may be caused by the growth and/or presence of gram positive and/or gram negative bacteria.
- bacterial infections may be caused by the growth and/or presence of aerobic and/or anaerobic bacteria.
- a bacterial infection may be caused by a bacterium selected from the group consisting of: Acinetobacter baumannii, Actinomyces israelii, Bacillus anthracis, Bacillus cereus, Bacteroides fragilis, Bartonella henselae, Bartonella quintana, Bordetella pertussis, Borrelia burgdorferi, Borrelia garinii, Borrelia afzelii, Borrelia recurrentis, Brucella abortus, Brucella canis, Brucella melitensis, Brucella suis, Campylobacter jejuni, Chlamydia pneumoniae, Chlamydia trachomatis, Chlamydophila pneumoniae, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, Corynebacterium diphtheriae, Enterococcus fa
- the methods of the invention may be applied to bacterial infections caused by a bacterium selected from the group consisting of: Streptococcus pneumoniae; Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae; Legionella pneumonia, Escherichia coli, and Haemophilus influenza.
- a bacterium selected from the group consisting of: Streptococcus pneumoniae; Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae; Legionella pneumonia, Escherichia coli, and Haemophilus influenza.
- the methods and medical uses of the invention are believed to have utility in helping to diagnose bacterial infections of prosthetic implants. These may include implants in the head or other body compartments. Merely by way of suitable example the methods of the invention may be able to correctly distinguish bacterial infection from mechanical failure in ventriculo-peritoneal (VP) shunts, using either blood or CSF samples. It is anticipated the methods of the invention would work equally well using body fluid from other implants, such as CSF from external ventricular drains in the head, or synovial fluid from the joint space around prosthetic knee replacements.
- VP ventriculo-peritoneal
- the methods and uses of the invention are particularly suitable for use in connection with bacterial infections in the lower respiratory tract, such as pneumonia as explained below.
- non-bacterial infection is an infection caused by the undesired presence and/or growth of a pathogen other than bacteria in a subject.
- non-bacterial infections may be caused by the growth and/or presence of viruses, parasites, protozoa and/or fungi, for example.
- the non-bacterial infections detected by methods of the invention may be caused by the growth and/or presence of viruses.
- a non-bacterial infection may be caused by a pathogen selected from the group consisting of: influenza A, influenza B, human adenoviruses such as adenovirus 4 and 7, human respiroviruses, human rubulaviruses, human coronaviruses, Human orthopneumovirus, Cryptosporidium parvum, Cryptosporidium hominis, Human rhinoviruses, HIV, Plasmodium falciparum , herpes simplex virus, poliovirus, rabies virus, measles virus, west nile virus, arenavirus, reovirus, Cryptococcus neoformans, Cryptococcus gatti, Histoplasma capsulatum, Human metapneumovirus, Respiratory syncytial virus, Parainfluenza virus, Coxsackievirus, Echovirus, Coronavirus such as MERS-CoV or SARS, Hantavirus, Epstein-Barr virus, Cytomegalovirus, Human herpes virus
- a pathogen
- the methods of the invention may be applied to non-bacterial infections caused by viruses selected from: influenza A and influenza B.
- lower respiratory system infection refers to infection of a whole or part of the lower respiratory system caused by any form of pathogen.
- a lower respiratory system infection is an inflammation of the trachea, bronchi and/or lungs.
- the methods of the invention may be applied to lower respiratory system infections in a subject.
- Lower respiratory system infections may include pneumonia, bronchitis, lung abscesses, bronchiolitis, tuberculosis, and flu, for example.
- lower respiratory system infections are caused by a pathogen.
- bacteria typically associated with a lower respiratory system infection in human subjects may include: Streptococcus pneumoniae, Haemophilus influenzae, Streptococcus pyogenes, Staphylococcus aureus, Klebsiella pneumoniae, Enterobacteria (for example Escherichia coli ), Streptococcus agalactiae, Moraxella catarrhalis, Bordatella pertussis, Chlamydophila pneumoniae, Chlamydophila psittaci, Mycoplasma pneumoniae, Legionella pneumophila, acinetobacter baumannii, Neisseria meningitidis, Coxiella burnetiid, Corynebacterium diphtheriae, Bordatella parapertussis, Neisseria gonorrhoeae, Campylobacter jejuni, and Listeria monocytogenes.
- non-bacterial pathogens typically associated with lower respiratory system infection in human subjects may include: influenza A, influenza B, human adenoviruses, human respiroviruses, human rubulaviruses, human coronaviruses, Human orthopneumovirus, Cryptosporidium parvum, Cryptosporidium hominis , and Human rhinoviruses.
- the methods of the invention may be applied to bacterial lower respiratory system infections.
- the methods of the invention may be applied to non-bacterial lower respiratory system infections, such as viral lower respiratory system infections.
- the methods of the invention may be applied to a lower respiratory system infection caused by one or more of the following pathogens: Streptococcus pneumoniae, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus pyogenes, Pseudomonas aeruginosa, Bordatella pertussis, Neisseria meningitidis, Coxiella burnetiid, Corynebacterium, Klebsiella pneumoniae; Legionella pneumonia, Escherichia coli, Haemophilus influenza, Moraxella catarrhalis, Mycoplasma pneumoniae, Acinetobacter baumannii, Chlamydophila ( Chlamydia ) pneumoniae, Bordatella parapertussis, Neisseria gonorrhoeae, Campylobacter jejuni, Listeria monocytogenes, Influenza virus A and B, Rhinovirus, Respiratory s
- the methods of the invention may be applied to a lower respiratory system infection caused by one or more of the following bacterial pathogens: Streptococcus pneumoniae, Haemophilus influenza, Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Legionella pneumonia, Moraxella catarrhalis, Mycoplasma pneumoniae, Chlamydophila psittaci, Coxiella burnetii, Francisella tularensis, Mycobacteria tuberculosis, and Chlamydophila ( Chlamydia ) pneumoniae.
- Streptococcus pneumoniae Haemophilus influenza
- Staphylococcus aureus Klebsiella pneumoniae
- Escherichia coli Escherichia coli
- Pseudomonas aeruginosa Legionella pneumonia
- Moraxella catarrhalis Mycoplasma pneumoniae
- the methods of the invention may be applied to a lower respiratory system infection caused by one or more of the following non-bacterial pathogens: Influenza virus A and B, Rhinovirus, Respiratory syncytial virus, Histoplasma capsulatum , Human metapneumovirus, Cryptococcus neoformans, Cryptococcus gatti, Coccidioides immitis, Adenovirus 4 and 7, Parainfluenza virus, Coxsackievirus, Echovirus, Coronavirus (MERS-CoV, SARS), Hantavirus, Epstein-Barr virus, Cytomegalovirus, Herpes simplex virus, Human herpesvirus 6 and Varicella-zoster virus.
- the methods of the invention may be applied to a lower respiratory system infection caused by one or more of the following pathogens: Streptococcus pneumoniae; Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae; Legionella pneumonia, Escherichia coli, Haemophilus influenza, and Influenza virus A and B.
- the methods of the invention are able to distinguish between bacterial and non-bacterial lower respiratory system infections.
- particular pathogens may be associated with particular lower respiratory system infections.
- pneumonia may be caused by any of the following pathogens: Chlamydia pneumoniae, Escherichia coli, Haemophilus influenza, Klebsiella pneumoniae, Legionella pneumonia, Moraxella catarrhalis, Mycoplasma pneumoniae, Neisseria meningitides, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus agalactiae, and Streptococcus pneumoniae.
- pathogens Chlamydia pneumoniae, Escherichia coli, Haemophilus influenza, Klebsiella pneumoniae, Legionella pneumonia, Moraxella catarrhalis, Mycoplasma pneumoniae, Neisseria meningitides, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus agalactiae, and Streptococcus pneumoniae.
- the methods of the invention may be applied to pneumonia in a subject.
- the pneumonia may be viral, bacterial, fungal or parasitic.
- the methods of the invention may be applied to pneumonia caused by one or more of the following pathogens: Chlamydia pneumoniae, Escherichia coli, Haemophilus influenza, Klebsiella pneumoniae, Legionella pneumonia, Moraxella catarrhalis, Mycoplasma pneumoniae, Neisseria meningitides, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus agalactiae, and Streptococcus pneumoniae.
- bacterial infection syndrome refers to conditions caused by, or resulting from, the presence of a bacterial infection in a subject. Such conditions may be systemic or isolated to a particular tissue or organ of the body.
- a bacterial infection syndrome may be caused by a subject's response to a bacterial infection.
- a bacterial infection syndrome may be caused by or associated with inflammation and/or injury of tissue(s) or organ(s)due to a bacterial infection.
- a bacterial infection syndrome may involve a particular tissue or organ, or may involve multiple tissues or organs.
- a bacterial infection syndrome involving a particular tissue or organ may be selected from: pneumonia (inflammation of the lower respiratory tract), pyelonephritis, urinary tract infection, gastroenteritis, cellulitis, impetigo, meningitis and osteomyelitis.
- a bacterial infection syndrome involving multiple tissues or organs may be selected from sepsis.
- the methods of the invention may be applied to a bacterial infection syndrome.
- the methods of the invention may be applied to sepsis and/or bacterial gastroenteritis.
- bacteria typically associated with sepsis in human subjects may include: Staphyloccocus species (e.g. Staphylococcus aureus ), Streptococcus pyogenes, Escherichia coli, Pseudomonas aeruginosa, Klebsiella species, Streptococcus pneumonia and Neisseria meningitidis.
- Staphyloccocus species e.g. Staphylococcus aureus
- Streptococcus pyogenes e.g. Staphylococcus aureus
- Escherichia coli eudomonas aeruginosa
- Klebsiella species e.g. Streptococcus pneumonia
- Neisseria meningitidis e.g. Staphyloccocus species
- Streptococcus pyogenes e.g. Staphylococcus aureus
- the methods of the invention may be applied to sepsis caused by a bacterium including: Staphyloccocus species (e.g. Staphylococcus aureus ), Streptococcus pyogenes, Escherichia coli, Pseudomonas aeruginosa, Klebsiella species, Streptococcus pneumonia and Neisseria meningitidis .
- Staphyloccocus species e.g. Staphylococcus aureus
- Streptococcus pyogenes e.g. Staphylococcus aureus
- Streptococcus pyogenes e.g. Staphylococcus aureus
- Streptococcus pyogenes e.g. Staphylococcus aureus
- Escherichia coli eudomonas aeruginosa
- Klebsiella species e.g. Strept
- bacteria typically associated with gastroenteritis in human subjects may include: Escherichia coli, Campylobacter jejuni, Salmonella enterica, Shigella dysenteriae.
- the methods of the invention may be applied to bacterial gastroenteritis caused by a bacterium including: Escherichia coli, Campylobacter jejuni, Salmonella enterica, Shigella dysenteriae.
- the methods of the first, second and third aspects of the invention are methods for detecting an infection, detecting a bacterial infection and detecting a non-bacterial infection, respectively.
- detecting is taken as meaning determining the presence of an infection, in particular a bacterial and/or a non-bacterial infection in a subject.
- the methods of the invention may be used to detect lower respiratory system bacterial and/or non-bacterial infections, suitably which may be caused by any of the pathogens described in the relevant sections above.
- the methods of the invention may be used to detect bacterial infection syndromes, suitably which may be caused by any of the pathogens described in the relevant section above.
- the method of the invention may be used to detect an infection that is associated with symptoms in a subject.
- the methods may also be used to detect an infection that is essentially asymptomatic.
- Such asymptomatic infections may be infections that are at a very early stage.
- one such advantage may be that target molecules indicative of expression of such genes are found at detectable levels at earlier time points than are potential markers expressed by the bacteria associated with the infection. While levels of expression of bacterial genes may be difficult to detect, especially during the early stages of bacterial infections, the expression of host genes may be readily assessed. The greater abundance of such target molecules indicative of expression of host response genes not only allows such assessments to be made at an earlier time, but may also improve the accuracy of the assessment.
- the methods of the invention which involve assaying a sample representative of gene expression to obtain data indicative of the relative abundance of target molecules indicative of the expression of genes associated with the subject's host response to bacterial infections may be useful in determining the presence of a non-bacterial infection. This is due to the ability to rule out a bacterial infection based on the relative gene expression data. As mentioned above, ruling out a bacterial infection is advantageous as it prevents the subject from receiving unnecessary antibiotic treatment, reduces healthcare costs, and reduces risk of developing antibiotic resistance.
- an infection may be a combined bacterial and non-bacterial infection.
- the inventors believe that the methods of first and second aspects of the invention may also be useful in detecting the presence of a bacterial infection in such a combined infection.
- the methods of the invention are methods are particularly suitable for use in detecting a lower respiratory system infection in a subject, whether it be a bacterial or non-bacterial infection.
- an additional step may optionally be practiced, to confirm the detection.
- the additional step may comprise performing a further diagnostic test for a lower respiratory system infection.
- Such a further diagnostic test may be used to identify the bacterial pathogen present, if the infection is determined to be bacterial, or to provide information regarding the susceptibility of the bacterial pathogen to antimicrobial agents.
- Bacterial culture is an example of a test which may be used to identify the bacterial pathogen and/or its susceptibility to antimicrobial agents
- the further diagnostic test may comprise a chest x-ray. Bacteria collected as part of the further diagnostic test may be investigated by culturing.
- the tenth aspect of the present invention allows the monitoring of the effectiveness of a treatment for an infection.
- the present inventors have discovered that the methods of detecting an infection of the invention still function to a high level of accuracy and specificity after a subject has begun receiving treatment for an infection. Therefore, the data indicative of the relative abundance of target molecules indicative of the expression of one or more gene pairs associated with the subject's host response can be measured before treatment and during treatment and after treatment.
- data indicative of the relative abundance of target molecules indicative of the expression of one or more gene pairs associated with the subject's host response can be used to monitor the progression of an infection during treatment, and thereby the effectiveness of said treatment.
- the data indicative of the relative abundance of target molecules indicative of the expression of one or more gene pairs from the first sample and second sample is analysed.
- the data indicative of the relative abundance of target molecules indicative of the expression of one or more gene pairs from the first sample and second sample is analysed to calculate the relative abundance ratio of the one or more gene pair(s) in the first sample and second sample as explained elsewhere herein.
- comparing the data indicative of the relative abundance of the target molecules in the first sample and second sample comprises comparing the relative abundance ratio of the one or more gene pair(s) in the first sample and second sample.
- a difference in the relative abundance of target molecules indicative of the expression of at least one gene pair between the first sample and second sample comprises a difference in the relative abundance ratio of the one or more gene pair(s) between the first sample and second sample.
- a difference in the relative abundance ratio of the one or more gene pair(s) between the first sample and second sample indicates a change in respect of the progress of the infection.
- the change in respect of the progress of the infection may be caused by the infection itself or may be in response to treatment.
- the change in respect of the progress of the infection may be an improvement or a worsening in the infection.
- an increase in the relative abundance of target molecules indicative of the expression of at least one gene pair between the first sample and second sample indicates a worsening in respect of the infection.
- an increase in the relative abundance of the target molecules indicative of the expression of at least one gene pair between the first sample and second sample indicates the treatment is ineffective.
- an increase in the relative abundance ratio of the one or more gene pair(s) between the first sample and the second sample indicates a worsening in respect of the infection, and suitably indicates that the treatment is ineffective.
- a decrease in the relative abundance of the target molecules indicative of the expression of at least one gene pair between the first sample and second sample indicates an improvement in respect of the infection.
- a decrease in the relative abundance of the target molecules indicative of the expression of at least one gene pair between the first sample and second sample indicates the treatment is effective.
- a decrease in the relative abundance ratio of the one or more gene pair(s) between the first sample and the second sample indicates an improvement in respect of the infection, and suitably indicates that the treatment is effective.
- the first sample is taken at a first timepoint and the second sample is taken at a second timepoint.
- the second time point is after treatment is provided to the subject.
- Suitable treatments for bacterial and non-bacterial infections are described elsewhere herein.
- the relevant bacterial or non-bacterial treatment is provided to the subject in accordance with the infection that has been diagnosed.
- the second sample is taken up to 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 7 hours, 10 hours, 12 hours, 15 hours, 20 hours, 24 hours, 48 hours, or 72 hours, after treatment is provided to the subject.
- the monitoring methods of the invention may make use of further samples at further timepoints (for example a third sample at a third timepoint, in addition to the first and second samples).
- the first, second (and any subsequent) timepoints may be separated by any time period during which it is wished to monitor the therapeutic effectiveness of a treatment.
- the time period may be hours, days, or weeks.
- the time period may be up to 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 7 hours, 10 hours, 12 hours, 15 hours, 20 hours, 24 hours, 48 hours, 72 hours, etc.
- the methods and medical uses are practiced in respect of a subject.
- the subject may be one requiring diagnosis or treatment for an infection, such as a bacterial or non-bacterial infection.
- the subject is one requiring diagnosis or treatment for a lower respiratory tract infection or a bacterial infection syndrome.
- the subject may be a human subject.
- the subject may be a patient undergoing medical care, or an individual requesting medical care.
- a suitable subject may be one believed to have a bacterial infection, such as a bacterial lower respiratory system infection or a bacterial infection syndrome.
- a suitable subject may have symptoms consistent with a lower respiratory system infection bacterial infection, such as shortness of breath, weakness, fever and/or a cough.
- the methods of the invention may be of use in definitively detecting or diagnosing a bacterial infection to warrant treatment with an antibiotic agent.
- a suitable subject may lack some or all symptoms consistent with a lower respiratory system infection. As considered elsewhere in this specification, such a subject may be substantially asymptomatic.
- a suitable subject in the context of the methods of the present invention may be one believed to be at risk of developing an infection, or suffering from an infection, such as a bacterial or non-bacterial lower respiratory system infection.
- an infection such as a bacterial or non-bacterial lower respiratory system infection.
- Such a subject may have been in contact with an individual suffering from a bacterial infection or non-bacterial infection, or may suffer from another disorder, which may render the subject at risk of developing a bacterial or non-bacterial infection.
- a suitable subject may be one already diagnosed with an infection, such as a bacterial or non-bacterial infection.
- the methods of the invention may be of use in monitoring the effectiveness of a treatment provided to the subject.
- the subject is human.
- the subject is male or female.
- the subject is an adult or a child.
- the methods of the invention make use of samples that are representative of gene expression in the subject in respect of whom the method is being practiced.
- the methods of the invention use samples representative of expression of host response genes involved in a subject's response to bacterial infection.
- Methods of the invention may make use of any sample which contains target molecules that provide a representation of such gene expression in the subject in question.
- the sample is a body fluid sample.
- suitable samples may include tissue samples, such as biopsies.
- tissue samples such as biopsies.
- a suitable sample (whether of a body fluid or tissue) may comprise biological cells from the subject that are involved in the host response to bacterial infection.
- a suitable body fluid sample may include: a blood sample (for example, a whole blood sample, a blood plasma sample, or a serum sample); or a cerebrospinal fluid (CSF) sample, or a synovial fluid sample.
- a blood sample for example, a whole blood sample, a blood plasma sample, or a serum sample
- CSF cerebrospinal fluid
- Blood samples are particularly suitable for use in the methods of the invention.
- the use of a blood sample (typically whole blood) is advantageous, since it is readily accessible. Additionally obtaining the sample is not associated with much less risk and patient discomfort than is the case for samples such as CSF, which is particularly advantageous in subjects with a suspected meningitis infection.
- Samples may be processed for the enrichment of target molecules. Suitable techniques for such enrichment may be determined with reference to the nature of the sample, and of the target molecule in question. Generally, examples of suitable techniques (such as techniques for the isolation of biological cells from a sample, and the preparation of the cells to yield gene transcripts) will be well known to those skilled in the art.
- Target molecules suitable for use in the method of the invention are any molecules which are representative of gene expression in the subject. Such target molecules may be representative of gene expression either directly or indirectly.
- a suitable target molecule which is directly representative of gene expression may comprise an RNA transcript.
- a suitable target molecule which is indirectly representative of gene expression may comprise a protein encoded by the gene.
- a suitable target molecule may be either directly indicative of gene expression (such as an RNA transcript), or indirectly indicative of gene expression (such as a protein encoded by an expressed gene).
- a sample that is essentially acellular the use of target molecules that are indirectly indicative of gene expression may be preferred, since such target molecules (an in particular protein examples of such target molecules) may be shed into the sample, even in the absence of biological cells.
- the nature of the target molecule and therefore the nature of the sample representative of gene expression, may be chosen in order to be consistent with use in a preferred assaying system.
- the sample is assayed to determine the relative abundance of the target molecules indicative of the gene expression of interest.
- techniques suitable for assaying gene expression in order to provide information regarding relative abundance will be known to the person skilled in the art.
- a suitable assay technique may be chosen with reference to the nature of the sample and the target molecules.
- gene expression can be measured directly by techniques that allow the detection and quantification of RNA target molecules, such as RT-PCR, real-time PCR, Northern blot, RNA sequencing (RNA-seq) and RNA microarray.
- RNA target molecules such as RT-PCR, real-time PCR, Northern blot, RNA sequencing (RNA-seq) and RNA microarray.
- Gene expression can be measured indirectly, by techniques that allow the detection and quantification of protein target molecules, such as ELISA, radioimmunoassay, immunoprecipitation, Western blot and mass spectrometry.
- ELISA enzyme-linked immunosorbent assay
- radioimmunoassay enzyme-mediated immunosorbent assay
- immunoprecipitation protein-specific blot assay
- Western blot protein-specific blot
- mass spectrometry Other suitable techniques for assaying proteins may be known to the person skilled in the art.
- gene expression of multiple genes or multiple pairs of genes, as is of interest in the present invention may be measured simultaneously for example by a combinatorial assay.
- the methods of the invention may be conducted by multiplex PCR.
- the methods of the invention may be conducted by multiple PCR tests.
- each of the genes/gene pairs for use in the methods of the invention are suitable for detection by PCR.
- the methods of the invention involve obtaining data indicative of the relative abundance of relevant target molecules indicative of gene expression.
- data indicative of relative abundance may be taken as encompassing any data that are capable of being used in determining the presence of an infection, such as a bacterial or non-bacterial infection, in a subject.
- the data provide a quantitative indication of relative abundance of expression of members of gene pairs, for example with reference to relevant target molecules.
- the data indicative of relative abundance of target molecules may be analysed as further shown in the Examples section of this specification.
- the methods of the invention involve obtaining data indicative of the relative abundance of target molecules indicative of the expression of at least the gene pair DUSP1 and IFI27.
- These genes are first and second host response genes, respectively.
- the methods of the invention involve obtaining data indicative of the relative abundance of target molecules indicative of the expression of the gene pair DUSP1 and IF127 and optionally a further gene pair.
- the further gene pair may be selected from any of the gene pairs set out in Table 2.
- the further gene pair may be selected from the gene pairs set out in Table 3.
- methods of the invention may involve obtaining data indicative of the relative abundance of target molecules indicative of the expression of any one of the further gene pairs set out in Table 2, in addition to the gene pair DUSP1 and IFI27.
- methods of the invention may involve obtaining data indicative of the relative abundance of target molecules indicative of the expression of at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, or all further gene pairs set out in Table 2, in addition to the gene pair DUSP1 and IFI27.
- methods of the invention may involve obtaining data indicative of the relative abundance of target molecules indicative of the expression of any one of the further gene pairs set out in Table 3, in addition to the gene pair DUSP1 and IFI27.
- methods of the invention may involve obtaining data indicative of the relative abundance of target molecules indicative of the expression of at least one, at least two, at least three, at least four, or all further gene pairs set out in Table 3, in addition to the gene pair DUSP1 and IFI27.
- the further gene pair is ELANE and IF127.
- the further gene pairs are firstly ELANE and IFI27, and secondly DUSP1/SIGLEC1.
- the methods of the invention may involve obtaining data indicative of the relative abundance of target molecules indicative of the expression of additional gene pairs beyond those set out in tables 2 or 3.
- the expression of the genes and gene pairs is investigated by assaying the sample for target molecules indicative of the expression of such host response genes, as referred to above.
- the step of determining comprises using the data indicative of the relative abundance of target molecules indicative of the expression of the one or more gene pair(s) to perform discriminant analysis.
- discriminant analysis or discriminant function analysis is a method used to find a combination of features (for example expression levels for a combination of host response genes) that separates two classes (for example bacterial infections from non-bacterial infections).
- the combination of features may be the expression levels of one or more gene pair(s) under consideration.
- the expression levels of the one or more gene pair(s) under consideration are determined from the data indicative of the relative abundance of target molecules indicative of the expression of the host response genes in each of the one or more gene pair(s).
- the presence of a bacterial infection in the subject is determined to be present if the relative abundance of target molecules indicative of the expression of the one or more gene pair(s) under analysis satisfies a predetermined condition.
- the presence of a non-bacterial infection is determined in a subject where the relative abundance of target molecules indicative of the expression of the one or more gene pair(s) under analysis don't satisfy the predetermined condition.
- Suitable combinations of features i.e. gene pairs that may be employed in the methods of the invention are described herein, as are the means to determine the expression levels of one or more genes in each gene pair using the relative abundance of target molecules.
- the predetermined condition is satisfied if the calculated result of the discriminant analysis exceeds a predetermined threshold.
- a predetermined threshold An example of a suitable predetermined threshold that may be employed with reference to a discriminant analysis is described in the examples section.
- the result of the discriminant function analysis provides the resulting relative abundance calculation which is suitable for use with the combination of gene pair(s) under consideration.
- the relative abundance calculation provides the relative abundance ratio of the one or more gene pair(s) under analysis.
- the relative abundance ratio of the one or more gene pair(s) is compared to a predetermined threshold.
- the step of determining comprises calculating the relative abundance ratio of the one or more gene pair(s) under consideration.
- the relative abundance ratio of the one or more gene pair(s) is a ratio of the abundance of the first listed gene(s) relative to the abundance of the second listed gene(s) in the or each gene pair.
- the presence of a bacterial infection in the subject is determined to be present if the abundance of the first listed gene(s) is increased relative to the abundance of the second listed gene(s).
- the presence of a non-bacterial infection in the subject is determined to be present if the abundance of the second listed gene(s) is increased relative to the abundance of the first listed gene(s).
- an increase in the abundance of DUSP1 relative to the abundance of IFI27 in a sample indicates the presence of a bacterial infection in a subject.
- an increase in the abundance of IFI27 relative to the abundance of DUSP1 in a sample indicates the presence of a non-bacterial infection in a subject.
- the step of determining comprises calculating the relative abundance ratio of the one or more gene pair(s) under consideration using a relative abundance calculation.
- the relative abundance calculation is determined using discriminant analysis as explained above.
- the relative abundance calculation is a linear equation.
- the relative abundance ratio is calculated from a relative abundance calculation such as:
- the step of determining further comprises assessing whether the result of the relative abundance calculation is above a predetermined threshold.
- the result of the calculation is the relative abundance ratio (D).
- the presence of a bacterial infection in the subject is determined to be present if the result of the discriminant function satisfies a predetermined condition.
- the presence of a bacterial infection in the subject is determined to be present if the relative abundance ratio satisfies a predetermined condition.
- the presence of a non-bacterial infection in the subject is determined to be present if the result of the discriminant function does not satisfy a predetermined condition.
- the presence of a non-bacterial infection in the subject is determined to be present the relative abundance ratio does not satisfy a predetermined condition.
- the determining step comprises comparing the relative abundance ratio of the one or more gene pair(s) under consideration to a predetermined threshold value.
- the determining step comprises determining whether the relative abundance ratio of the one or more gene pair(s) under consideration exceeds a predetermined threshold.
- the predetermined threshold is a relative abundance ratio of at least 1.18.
- the predetermined threshold is D>1.18.
- the determining step comprises determining whether the relative abundance ratio of the one or more gene pair(s) under consideration exceeds 1.18.
- the presence of a bacterial infection in the subject is determined to be present if the relative abundance ratio of the one or more gene pair(s) under consideration satisfies the predetermined condition.
- the presence of a bacterial infection in the subject is determined to be present if one or more of the gene pair(s) under consideration has a relative abundance ratio of greater than 1.18.
- the presence of a non-bacterial infection in the subject is determined to be present if relative abundance ratio of the one or more of gene pair(s) under consideration has a relative abundance ratio which does not satisfy a predetermined condition.
- the presence of a non-bacterial infection in the subject is determined to be present if one or more of the gene pairs under consideration has a relative abundance ratio of less than 1.18.
- the methods of the invention are able to determine the presence of an infection, and are able to distinguish between bacterial and non-bacterial infections, with at least 70%, at least 80%, at least 90%, at least 95% or 100% sensitivity.
- the methods of the invention are able to determine the presence of an infection, and are able to distinguish between bacterial and non-bacterial infections, with at least 70%, at least 80%, at least 90%, at least 95% or 100% specificity.
- the methods of the invention are able to determine the presence of an infection, and are able to distinguish between bacterial and non-bacterial infections, with at least 70%, at least 80%, at least 90%, at least 95% or 100% accuracy.
- the methods of the invention are able to determine the presence of an infection, and are able to distinguish between bacterial and non-bacterial infections, with 100% sensitivity, 100% specificity and 100% accuracy.
- the examples provided herein advantageously demonstrate that testing for the relative abundance of transcripts of the gene pair DUSP1 and IFI27, provides 100% sensitivity, accuracy and specificity in determining the cause of an infection in patients. This level of sensitivity, accuracy and specificity is maintained when combined with testing for the relative abundance of transcripts of other gene pairs.
- the eighth aspect of the invention relates to a method of treating an infection in a subject, the method comprising:
- the infection may be a bacterial infection or a non-bacterial infection. This embodiment gives rise to additional aspects of the invention.
- the invention relates to a method of treating a bacterial infection in a subject, the method comprising:
- the invention relates to a method of treating a non-bacterial infection in a subject, the method comprising:
- treatment of bacterial infections will generally involve the provision of antibacterial agents to a subject requiring such treatment.
- Suitable antibacterial agents include antibiotics such as those selected from the group consisting of: third generation cephalosporins (e.g. ceftriaxone, cefotaxime), ampicillin, penicillin G, meropenem, fluoroquinolone, trimethoprim-sulfamethoxazole, and chloamphenicol.
- an antibacterial agent for use in accordance with this aspect of the invention may be selected with reference to the nature of the bacteria giving rise to the bacterial infection, such as bacterial meningitis, to be treated.
- an antibacterial agent for use in accordance with this aspect of the invention may be selected from the group of: vancomycin plus a third-generation cephalosporin; ceftriaxone or cefotaxime; Meropenem (C-III), fluoroquinolonec (B-II).
- an antibacterial agent for use in accordance with this aspect of the invention may be selected from the group of: a third-generation cephalosporin; Ceftriaxone; Penicillin G, ampicillin, chloramphenicol, fluoroquinolone, aztreonam.
- an antibacterial agent for use in accordance with this aspect of the invention may be selected from the group of: Ampicillin (optionally with addition of an aminoglycoside) or penicillin G (optionally with addition of an aminoglycoside) Trimethoprim-sulfamethoxazole, meropenem (B-III).
- an antibacterial agent for use in accordance with this aspect of the invention may be selected from the group of: Ampicillind or penicillin G (optionally with addition of an aminoglycoside) Third-generation cephalosporins (B-III).
- an antibacterial agent for use in accordance with this aspect of the invention may be selected from the group of: Third-generation cephalosporin, Ceftriaxone; (A-I) Chloramphenicol, cefepime (A-I), meropenem (A-I), fluoroquinolone.
- an antibacterial agent for use in accordance with this aspect of the invention may be selected from the group of: Third-generation cephalosporin, ceftriaxone, (A-II) Cefepime, meropenem, aztreonam, fluoroquinolone, trimethoprim-sulfamethoxazole.
- treatment of non-bacterial infections may involve treatment with an anti-viral, an anti-parasitic, an anti-protozoan, or an anti-fungal agent as appropriate to the infection.
- an anti-viral agent may be selected from the group consisting of an adamantane anti-viral agent, a chemokine receptor antagonist, an anti-viral interferon, an integrase strand transfer inhibitor, a neuraminidase inhibitor, a non-nucleoside reverse transcriptase inhibitor, a non-structural protein 5A (NS5A) inhibitor, a nucleoside reverse transcriptase inhibitor, a protease inhibitor and purine nucleoside.
- adamantane anti-viral agent a chemokine receptor antagonist
- an anti-viral interferon an integrase strand transfer inhibitor
- a neuraminidase inhibitor a non-nucleoside reverse transcriptase inhibitor
- a non-structural protein 5A (NS5A) inhibitor non-structural protein 5A (NS5A) inhibitor
- NSS5A non-structural protein 5A
- nucleoside reverse transcriptase inhibitor a prote
- an anti-parasitic agent may be selected from the group consisting of Artemether, Albendazole, Amphotericin B, Eflornithine, Furazolidone, Ivermectin, Mebendazole, Melarsoprol, Metronidazole, Nifursemizone, Nitazoxanide, Ornidazole, Paromomycin sulphate, Pentamidine, Praziquantal, Pyrimethamine, Quinapyramine, Rifampicin, Tinidazole
- an anti-fungal agent may be selected from the group consisting of Abafungin, Albaconazole, Anidulafungin, Bifonazole, Butoconazole, Caspofungin, Clotrimazole, Econazole, Efinaconazole, Epoxiconazole, Fenticonazole, Fluconazole, lsoconazole, Ketoconazole, Luliconazole, Micafungin, Miconazole, Omoconazole, Oxiconazole, Sertaconazole, Sulconazole, Tioconazole, Isavuconazole, Itraconazole, Posaconazoie, Propiconazole, Ravuconazole, Terconazole, Voriconazoie.
- RNA stabilising tubes PAXgene
- Total RNA was extracted using Blood RNA Extraction kits (PAXgene) following the manufacturer instructions.
- Total RNA 500 ng per sample was amplified and labelled using Low Input Quick Amp. Labelling kits (Agilent).
- Patient sample derived amplified RNA was labelled with Cyanine-3.
- Control human amplified RNA Universal RNA was labelled with Cyanine-5.
- Labelled RNA 200 ng was hybridised to SurePrint G3 GE 8x60K (Design ID 030495) human-specific microarrays following the manufacturers' instructions (Agilent Technologies).
- Arrays were scanned using Agilent G2505C scanner (Agilent Technologies). Raw fluorescent intensity was measured and initial quality control assessment undertaken using Agilent Feature Extraction software (FE 10.5.1.1). Transcripts exhibiting a statistically significant difference in relative transcript abundance between proven bacterial cases and proven non-bacterial cases were identified based on the fold change and false detection rate (FDR) output from SAM 4.0. (http://wwwstat.stanford.edu/ ⁇ tibs/SAM). Gene-expression micro-array analysis of the patients' blood samples confirmed multiple genes exhibited differential abundance in the host response to bacterial compared to non-bacterial (in this case viral) respiratory infections ( FIG. 1 ).
- Identifying top scoring pairs of markers For our diagnostic, we aimed to identify pairs of markers (gene transcripts), where the first marker exhibited consistently higher expression than the 2nd marker in bacterial pneumonia cases. However in the comparator clinical group (viral infection), the expression ratio between the two markers changes, so that the 2nd marker, shows relatively consistent higher expression than the 1st marker.
- the “Top Scoring Pairs” of genes (TSPs) were identified using the open source program AUREA (Adapative Unified Relative Expression Analyser).
- Validating marker gene pairs on a PCR platform The most accurate TSPs based on the microarray data were re-tested using quantitative RT-PCR to confirm diagnostic accuracy on a measurement platform routinely available in hospital laboratories.
- One reason for assessing marker performance is that shorter sequences are interrogated (typically 20mer) using PCR compared to arrays (>60mer). This can affect marker performance.
- TSPs were tested using our original patient samples, so we could compare performance. Pairs were tested via proprietary TaqMan primer/probe sets (one probe set against each transcript). Probes were exon-spanning and biased towards the 3′ end of mRNA. In pairs showing poor discrimination between groups, primers were re-designed based on array sequence. TSPs showing consistent performance by RT-PCR went forward.
- identification of the sample being as indicative of bacterial infection by relative transcript marker abundance ratio can also be arrived at using different equations.
- Transcript marker pair specificity (with sensitivity set at 100%) in the respiratory sample set are shown in Table 4 and FIG. 2 .
- the 5 transcript markers distinguished bacterial pneumonia from viral infection with a sensitivity of 100% (12/12) and a specificity of 100% (18/18) as shown in table 6.
- Paediatric patients with a wider range of bacterial infection syndromes including pneumonia, bacteraemia, urinary tract infection, pyelonephritis, abscess, meningitis and septic arthritis were examined.
- the transcript markers distinguished bacterial from viral infection with a sensitivity of 100% (58/58) and a specificity of 89% (16/18), see Table 7.
- Table 8 shows paediatric bacteraemia patients presenting to hospital with acute illness caused by Gram negative ( E. coli ) or Gram positive ( S. aureus or S. pneumonia ) bacteria present in the blood stream that were analysed. Diagnosis was established
- TSPs E/44-ELANE/IFI44L; E/I-ELANE/IFI27; D/44-DUSP1/IFI44L; D/I-DUSP1/IFI27; E/S-ELANE/SIGLEC1; D/S-DUSP1/SIGLEC1
- TSP performance using micro-array data from patients with proven bacterial infection and proven malaria.
- RNA expression values from microarray analysis of RNA from blood of adult patients with Plasmodium falciparum malaria were compared with the gene expression levels in patients with bacterial meningitis for the following transcript markers: DUSP1, IF127 and IF144L.
- these 3 transcript markers were able to classify cases of infections of bacterial meningitis from cases of P. falciparum malaria with a sensitivity of 100%, specificity of 93% and accuracy of 94% (Table 10)
- transcript marker gene pairs E/44-ELANE/IF144L; E/I-ELANE/IF127; D/44-DUSP1/IF144L; D/I-DUSP1/1F127; E/S-ELANE/SIGLEC1; D/S-DUSP1/SIGLEC1
- Tester was blinded to sample classification. The lower threshold of expression ratio for classifying a bacterial sample was set as ⁇ 1.2 standard deviations below the mean expression ratio based on the bacterial samples previously measured. Unblinding, the test appeared to identify only 18/26 bacterial samples.
- multiple bacterial samples were collected more than 5 days after initiation of intravenous antibiotics. There was a marked reduction in the transcript maker pairs expression ratio among patients exposed to over 5 days of antibiotics showing that the treatment was effective ( FIG. 3 ).
- test Analysing bacterial samples collected within 5 days, the test exhibited 100% (13/13) sensitivity and 90% (135/150) specificity. Distinguishing between proven bacterial and viral infection the test exhibited 100% (13/13) sensitivity and 98% (51/52) specificity. This observation indicates the test can still accurately and sensitively detect bacterial infection up to 5 days after initiation of antibiotics. The observation also indicates that the test of the invention can be used to monitor treatment and help confirm the infection is resolving after treatment has been provided to a subject.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to methods of detecting an infection in a subject based on the relative abundance of target molecules indicative of the expression of at least the gene pair DUSP1 and IFI27. In particular, the invention relates to a method of distinguishing between a bacterial infection or a non-bacterial infection in a subject, especially between bacterial and non-bacterial lower respiratory system infections using the gene pair. Further, the invention provides the medical use of therapeutic agents in the treatment of a bacterial or non-bacterial infection in a subject identified as having such an infection through use of a method of the invention, and monitoring the therapeutic effectiveness.
Description
- The present invention relates to methods of detecting an infection in a subject. In particular, the invention also relates to methods of detecting a bacterial infection and methods of detecting a non-bacterial infection in a subject. The present invention also relates to a method of distinguishing between a bacterial infection or a non-bacterial infection in a subject, especially between bacterial and non-bacterial lower respiratory system infection. Further, the invention provides the medical use of therapeutic agents in the treatment of a bacterial or non-bacterial infection in a subject identified as having such an infection through use of a method of the invention. The invention also relates to a method of treating an infection in a subject, and a method of detecting relative abundance of target molecules in a subject suspected of having or developing an infection.
- Infections, both bacterial and non-bacterial are a significant cause of morbidity and mortality in UK and worldwide. Infections can involve body compartments, organs or indeed the whole body. If left undiagnosed and untreated, infections can lead to sepsis, disability and sometimes loss of life.
- Infections in some body compartments, such as the respiratory tract, can be difficult to diagnose because bacterial and viral infections, for example, present in the patient with the same symptoms.
- Current methods of diagnosis for such infections are slow and laborious, typically involving samples being sent to a laboratory for testing with the results being provided after several days. For example, blood cultures often remain negative for a long time if the infection is caused by a slow growing bacteria. By this time, the infection may have spread considerably and have become unmanageable.
- To combat this, patients are often given broad spectrum antibiotic treatment in case the infection is bacterial despite the lack of results confirming the presence of bacteria. This increases the cost of treatment that may not be effective and leads to the development of antibiotic resistance in the bacterial population.
- It is an object of one or more of the aspects of the present invention to address the above-mentioned problems in the art.
- In a first aspect, the invention relates to a method of detecting an infection in a subject, the method comprising:
-
- (a) assaying a sample representative of gene expression in the subject to obtain data indicative of the relative abundance of target molecules indicative of the expression of at least the gene pair DUSP1 and IF127;
- (b) determining the presence of an infection in the subject in dependence on the data.
- In a second aspect, the invention relates to method of detecting a bacterial infection in a subject, the method comprising:
-
- (a) assaying a sample representative of gene expression in the subject to obtain data indicative of the relative abundance of target molecules indicative of the expression of at least the gene pair DUSP1 and IF127;
- (b) determining the presence of a bacterial infection in the subject in dependence on the data.
- In a third aspect, the invention relates to a method of detecting a non-bacterial infection in a subject, the method comprising:
-
- (a) assaying a sample representative of gene expression in the subject to obtain data indicative of the relative abundance of target molecules indicative of the expression of at least the gene pair DUSP1 and IF127;
- (b) determining the presence of a non-bacterial infection in the subject in dependence on the data.
- In a fourth aspect, the invention relates to a method of distinguishing between a bacterial infection and a non-bacterial infection in a subject, the method comprising:
-
- (a) assaying a sample representative of gene expression in the subject to obtain data indicative of the relative abundance of target molecules indicative of the expression of at least the gene pair DUSP1 and IFI27;
- (b) determining the presence of a bacterial infection or non-bacterial infection in the subject in dependence on the data.
- In a fifth aspect, the invention relates to a method of determining the cause of an infection in a subject, the method comprising:
-
- (a) assaying a sample representative of gene expression in the subject to obtain data indicative of the relative abundance of target molecules indicative of the expression of at least the gene pair DUSP1 and IFI27;
- (b) determining the cause of the infection as bacterial or non-bacterial in dependence on the data.
- In a sixth aspect, the invention relates to an antibacterial agent for use in the treatment of a bacterial infection in a subject identified as having a bacterial infection by a method according to first, second, fourth and fifth aspect.
- In a seventh aspect, the invention relates to a therapeutic agent for use in the treatment of a non-bacterial infection in a subject identified as having a non-bacterial infection by a method according to a first, third, fourth and fifth aspect.
- A method of the first aspect, in which an infection is detected in a subject, may further comprise a step of providing the subject with treatment for the pathogen-associated infection.
- Indeed, in an eighth aspect, the invention relates to a method of treating an infection in a subject, the method comprising:
-
- (a) assaying a sample representative of gene expression in the subject to obtain data indicative of the relative abundance of target molecules indicative of the expression of at least the gene pair DUSP1 and IFI27;
- (b) determining the presence of an infection in the subject in dependence on the data;
- (c) providing treatment for an infection when the determination indicates the presence of an infection.
- In a ninth aspect, the invention relates to a method of detecting the relative abundance of target molecules in a subject suspected of having or developing an infection, the method comprising:
-
- (a) providing a sample representative of gene expression in the subject suspected of having or developing a pathogen-associated infection;
- (b) detecting the relative abundance of target molecules indicative of the expression of at least the gene pair DUSP1 and IFI27.
- In a tenth aspect, the invention relates to a method of monitoring the therapeutic effectiveness of a treatment for a subject having an infection, the method comprising:
-
- (a) assaying a first sample representative of gene expression in the subject to obtain data indicative of the relative abundance of target molecules indicative of the expression of at least the gene pair DUSP1 and IFI27 in the first sample;
- (b) providing the treatment to the subject;
- (c) assaying a second sample representative of gene expression in the subject to obtain data indicative of the relative abundance of the same target molecules present in the second sample; and
- (d) comparing the relative abundance of the target molecules in the first and second samples;
wherein a difference between the data indicative of the relative abundance of the target molecules in the first and second samples indicates the therapeutic effectiveness of the treatment.
- A method of detecting an infection in a subject in accordance with the first aspect of the invention, or a method of detecting a bacterial infection in a subject in accordance with the second aspect of the invention, in which a bacterial infection is detected in a subject, may further comprise a step of conducting a further confirmatory test for the bacterial infection in the subject. Suitably, in such an embodiment, a bacterial infection is diagnosed when the results of both the first test (a method of the first and/or second aspect of the invention) and the second test (the confirmatory test) indicate the presence of bacterial infection. For example, a sample of biological fluid, such as CSF from lumbar puncture or blood from venepuncture, may be cultured in order to grow the microorganism associated with infection. This allows confirmation of bacterial infection and also allows determination of antimicrobial susceptibility of any isolated pathogen.
- By the same token, a method of detecting a non-bacterial infection in a subject, in accordance with the third aspect of the invention, in which a non-bacterial infection is detected in a subject, may further comprise a step of conducting a further confirmatory test for the non-bacterial infection in the subject. Suitably, in such an embodiment, a non-bacterial infection is diagnosed when the results of both the first test (a method of the first and/or second aspect of the invention) and the second test (the confirmatory test) indicate the presence of non-bacterial infection. For example, a sample of biological fluid, such as a sputum or blood, may be tested for the presence of DNA from a non-bacterial pathogen (such as a virus or parasite). This allows confirmation of non-bacterial infection and also allows determination of appropriate treatment.
- Methods in accordance with the first, second, third, fourth, fifth, eighth ninth, or tenth aspects of the invention may comprise obtaining data indicative of the relative abundance of target molecules indicative of the expression a further gene pair. Suitable examples of further gene pairs, and the benefits that may be gained by employing such further pairs, are described elsewhere in the present disclosure. Merely by way of example, further gene pairs particularly suitable for use in embodiments of the methods of invention may include at least one of: DUSP1 and SIGLEC1; ELANE and IFI27; DUSP1 and IFI44L; ELANE and SIGLEC1; or ELANE and IFI44L.
- Unless required so by the context, references to the methods of the invention may be taken as encompassing the detecting methods of the first, second, third or ninth aspects of the invention, or methods of distinguishing between bacterial infection and non-bacterial infection of the fourth aspect, or method of determining the cause of infection according to the fifth aspect, or method of treating according to the eight aspect (and therefore the medical uses of the sixth or seventh aspects), or method of monitoring according to the tenth aspect.
- Infections, regardless of whether they are bacterial or non-bacterial, typically present with identical or very similar symptoms. This makes diagnosis and choice of a correct therapeutic approach difficult. In many cases, patients are given empirical antibiotic treatment, despite the lack of results confirming the presence of bacteria. This often leads to unnecessary treatment with antibiotics, which increases the cost of treatment and may lead to the development of antibiotic resistance.
- The methods of the present invention provide simple tests that may be used for diagnosing infections, in particular for diagnosing and distinguishing between bacterial or non-bacterial infections. Such infections include, but are not limited to, lower respiratory tract infections, meningitis, and tropical diseases, for example malaria. Other examples of infections are discussed elsewhere in this specification.
- Accordingly, the methods of the invention are advantageous, because they may allow a swifter identification of patients with suspected bacterial infections, which in turn, allows medical staff to commence appropriate treatment promptly, as well as prevent patients with non-bacterial infections from receiving unnecessary antibiotics. This advantageously reduces the problem of antibiotic resistance among pathogenic bacteria. Moreover, the inventors have surprisingly found that the methods of the invention diagnose and distinguish between bacterial and non-bacterial infections with a very high degree of sensitivity and specificity.
- Furthermore, the methods of the present invention may allow the detection of bacterial infections, such as lower respiratory tract infections, even in cases where the sample is collected after the patients has already received antibiotics and/or other anti-microbial treatment. This is in contrast to conventional methods for detecting bacteria, such as bacterial culture, which often show poor sensitivity (fail to detect true cases of bacterial infection) when patient samples are collected after anti-microbial treatment has been initiated. Thus, the methods of the present invention may reduce the risk of missing true cases of bacterial infections among patients who have previously begun treatment with antibiotics.
- In addition, the methods of the present invention can be used to detect infections remote from the source of the infection. The methods rely on the detection of the expression of one or more gene pairs that can be detected in any sample such as a blood sample, without requiring a sample to be taken from where the infection may be present. For example, a CNS infection may be detected from a blood sample rather than requiring a cerebrospinal fluid (CSF) sample to be taken.
- The methods of the present invention are based on the inventors' selection of a specific gene pair, or combination of gene pairs, which allow(s) the detection of an infection, such as a bacterial or non-bacterial infection, as well as the distinction between a bacterial and non-bacterial infection.
- The invention will now be described with reference to the following figures in which:
-
FIG. 1 : Microarray data showing gene expression in community acquired pneumonia (CAP) patient samples from the UK via Agilent gene-expression micro-arrays (11 proven bacterial pneumonia, and six proven viral [influenza] pneumonia [bacteria proven by culture in blood and influenza proven by PCR on nasopharyngeal swab]). Based on relative transcript abundance (red (dark areas)—high abundance/green (light areas)—low abundance) across the samples, 87 transcripts were significantly (false detection rate <5% [p<0.05]) differentially expressed among the group of proven bacterial CAP compared to others; a sub-set of transcripts exhibiting differential abundance are shown inFIG. 1 . This data provided proof of principle that pairs of markers exhibiting reciprocal changes in expression between bacterial infections like bacterial CAP and viral infection mimics exist. -
FIG. 2 : A. Plot of expression ratio (Y-axis) for the six top scoring pairs of genes, from left to right: D/I-DUSP1/IFI27 [1]; E/I-ELANE/IFI27 [2]; D/S-DUSP1/SIGLEC1 [3]; E/S-ELANE/SIGLEC1 [4]; E/44-ELANE/IFI44L [5]; D/44-DUSP1/IFI44L [6]; measured via RT-PCR. Solid shapes represent bacterial pneumonia blood samples (n=13). Half-solid shapes represent viral respiratory [influenza] samples (n=6). The dotted horizontal line represents the predetermined threshold for the relative abundance expression ratio for classifying a sample as having a bacterial infection B. Sensitivity (sens.) and specificity (spec.) of each marker pair; C. Specificity for the pairs when combined via Boolean operand (AND). Using one to six gene pairs increases overall specificity from 17 to 89%. -
FIG. 3 : Plot of expression ratio (Y-axis) for the six top scoring pairs of genes (E/44-ELANE/IFI44L; E/I- ELANE/IFI27; D/44- DUSP1/IFI44L; D/I-DUSP1/IFI27; E/S-ELANE/SIGLEC1; D/S-DUSP1/SIGLEC1) in bacterial infection samples (n=26). Each dot on the x-axis represents a sample. A different coloured/shaped dot on the y-axis corresponds to the same sample measured by a different gene pair. X-axis corresponds to the number of days the patient had been treated with antibiotics prior to sampling. There is a reduction in all gene pair expression abundance ratios among samples collected over 5 days after antibiotic initiation. Grouping patients by number of days on antibiotics (1-5, 6-10 and 11+ days) sensitivity was 1(13/13), 0.5 (3/6) and 0.28 (2/7) respectively. - In order to assist the understanding of the present invention, certain terms used herein will now be further defined in the following paragraphs.
- As used herein, the term “infection” refers the undesired presence and/or growth of a pathogen in a subject that has a negative effect on the subject's health and/or well-being. While the term “infection” should not be taken as encompassing the growth and/or presence of pathogens, such as bacteria, which are normally present in the subject (for example in the digestive tract of the subject), it may encompass the pathological overgrowth of such bacteria.
- An infection may involve any body compartment. Accordingly, methods or medical uses of the present invention are applicable to infection in any system, organ or area of the subject, such as, but not limited to, lower respiratory system, upper respiratory system, central nervous system, gastrointestinal system, urinary system, the ocular system, the auditory system, and/or the skin.
- Alternatively, the infection can also involve multiple body compartments, or in fact the whole body. Accordingly, methods and medical uses of the present invention are applicable to diseases such as bacteraemia, septicaemia, sepsis, Epstein-Barr virus infection, malaria, and helminthiasis.
- Suitably, the infection is a pathogen-associated infection. In a suitable embodiment, the infection may be bacterial or non-bacterial. Such an embodiment gives rise to the second and third aspects of the invention.
- Alternatively, the infection can be a combined bacterial and non-bacterial infection. For example, a bacterial infection may arise as a secondary infection due to a non-bacterial infection (such as a viral infection).
- In a suitable embodiment, a non-bacterial infection is selected from the group consisting of a viral, a parasitic, a protozoan and a fungal infection. More suitably, a non-bacterial infection is a viral or a parasitic infection. Examples of bacterial or non-bacterial infections are discussed hereinbelow.
- A “bacterial infection” is an infection caused by the undesired presence and/or growth of bacteria in a subject.
- In a suitable embodiment, bacterial infections may be caused by the growth and/or presence of gram positive and/or gram negative bacteria.
- In a suitable embodiment, bacterial infections may be caused by the growth and/or presence of aerobic and/or anaerobic bacteria.
- Merely by way of example, a bacterial infection may be caused by a bacterium selected from the group consisting of: Acinetobacter baumannii, Actinomyces israelii, Bacillus anthracis, Bacillus cereus, Bacteroides fragilis, Bartonella henselae, Bartonella quintana, Bordetella pertussis, Borrelia burgdorferi, Borrelia garinii, Borrelia afzelii, Borrelia recurrentis, Brucella abortus, Brucella canis, Brucella melitensis, Brucella suis, Campylobacter jejuni, Chlamydia pneumoniae, Chlamydia trachomatis, Chlamydophila pneumoniae, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, Corynebacterium diphtheriae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Ehrlichia canis, Ehrlichia chaffeensis, Francisella tularensis, Haemophilus influenzae, Helicobacter pylori, Klebsiella pneumoniae, Legionella pneumonia, Leptospira interrogans, Leptospira santarosai, Leptospira weilii, Leptospira noguchii, Listeria monocytogenes, Moraxella catarrhalis, Mycoplasma pneumoniae, Neisseria gonorrhoeae, Neisseria meningitidis, Nocardia asteroids, Pseudomonas aeruginosa, Rickettsia rickettsia, Salmonella typhi, Salmonella typhimurium, Shigella sonnei, Shigella dysenteriae, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, Treponema pallidum, Ureaplasma urealyticum, Vibrio cholera, Yersinia pestis, Yersinia enterocolitica, and Yersinia pseudotuberculosis.
- In one embodiment, the methods of the invention may be applied to bacterial infections caused by a bacterium selected from the group consisting of: Streptococcus pneumoniae; Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae; Legionella pneumonia, Escherichia coli, and Haemophilus influenza.
- The inventors believe that the methods or medical uses of the invention according to the first, second, fourth, fifth, sixth eighth and tenth aspects are applicable to bacterial infections in which the bacterial pathogens are selected from any of the groups set out herein.
- The methods and medical uses of the invention are believed to have utility in helping to diagnose bacterial infections of prosthetic implants. These may include implants in the head or other body compartments. Merely by way of suitable example the methods of the invention may be able to correctly distinguish bacterial infection from mechanical failure in ventriculo-peritoneal (VP) shunts, using either blood or CSF samples. It is anticipated the methods of the invention would work equally well using body fluid from other implants, such as CSF from external ventricular drains in the head, or synovial fluid from the joint space around prosthetic knee replacements.
- Without detracting from the above, the methods and uses of the invention are particularly suitable for use in connection with bacterial infections in the lower respiratory tract, such as pneumonia as explained below.
- A “non-bacterial infection” is an infection caused by the undesired presence and/or growth of a pathogen other than bacteria in a subject.
- In a suitable embodiment, non-bacterial infections may be caused by the growth and/or presence of viruses, parasites, protozoa and/or fungi, for example.
- In a suitable embodiment, the non-bacterial infections detected by methods of the invention may be caused by the growth and/or presence of viruses.
- Merely by way of example, a non-bacterial infection may be caused by a pathogen selected from the group consisting of: influenza A, influenza B, human adenoviruses such as
adenovirus 4 and 7, human respiroviruses, human rubulaviruses, human coronaviruses, Human orthopneumovirus, Cryptosporidium parvum, Cryptosporidium hominis, Human rhinoviruses, HIV, Plasmodium falciparum, herpes simplex virus, poliovirus, rabies virus, measles virus, west nile virus, arenavirus, reovirus, Cryptococcus neoformans, Cryptococcus gatti, Histoplasma capsulatum, Human metapneumovirus, Respiratory syncytial virus, Parainfluenza virus, Coxsackievirus, Echovirus, Coronavirus such as MERS-CoV or SARS, Hantavirus, Epstein-Barr virus, Cytomegalovirus,Human herpes virus 6, Varicella-zoster virus, and Coccidioides immitis. - In one embodiment, the methods of the invention may be applied to non-bacterial infections caused by viruses selected from: influenza A and influenza B.
- The inventors believe that the methods or medical uses of the invention according to the first, third, fourth, fifth, seventh, eighth and tenth aspects are applicable to non-bacterial infections in which the pathogens are selected from any of the groups set out herein.
- The term “lower respiratory system infection” as used herein, refers to infection of a whole or part of the lower respiratory system caused by any form of pathogen. In a suitable embodiment, a lower respiratory system infection is an inflammation of the trachea, bronchi and/or lungs.
- In one embodiment, the methods of the invention may be applied to lower respiratory system infections in a subject.
- Lower respiratory system infections may include pneumonia, bronchitis, lung abscesses, bronchiolitis, tuberculosis, and flu, for example. Suitably, lower respiratory system infections are caused by a pathogen.
- By way of example, bacteria typically associated with a lower respiratory system infection in human subjects may include: Streptococcus pneumoniae, Haemophilus influenzae, Streptococcus pyogenes, Staphylococcus aureus, Klebsiella pneumoniae, Enterobacteria (for example Escherichia coli), Streptococcus agalactiae, Moraxella catarrhalis, Bordatella pertussis, Chlamydophila pneumoniae, Chlamydophila psittaci, Mycoplasma pneumoniae, Legionella pneumophila, acinetobacter baumannii, Neisseria meningitidis, Coxiella burnetiid, Corynebacterium diphtheriae, Bordatella parapertussis, Neisseria gonorrhoeae, Campylobacter jejuni, and Listeria monocytogenes.
- By way of example, non-bacterial pathogens typically associated with lower respiratory system infection in human subjects may include: influenza A, influenza B, human adenoviruses, human respiroviruses, human rubulaviruses, human coronaviruses, Human orthopneumovirus, Cryptosporidium parvum, Cryptosporidium hominis, and Human rhinoviruses.
- In some embodiments, the methods of the invention may be applied to bacterial lower respiratory system infections.
- In some embodiments, the methods of the invention may be applied to non-bacterial lower respiratory system infections, such as viral lower respiratory system infections.
- Suitably, the methods of the invention may be applied to a lower respiratory system infection caused by one or more of the following pathogens: Streptococcus pneumoniae, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus pyogenes, Pseudomonas aeruginosa, Bordatella pertussis, Neisseria meningitidis, Coxiella burnetiid, Corynebacterium, Klebsiella pneumoniae; Legionella pneumonia, Escherichia coli, Haemophilus influenza, Moraxella catarrhalis, Mycoplasma pneumoniae, Acinetobacter baumannii, Chlamydophila (Chlamydia) pneumoniae, Bordatella parapertussis, Neisseria gonorrhoeae, Campylobacter jejuni, Listeria monocytogenes, Influenza virus A and B, Rhinovirus, Respiratory syncytial virus, Human metapneumovirus,
Adenovirus 4 and 7, Respiroviruses, Rubulaviruses, Parainfluenza virus, Coxsackievirus, Echoviruses, Coronaviruses (MERS-CoV, SARS), Hantavirus, Orthopneumovirus, Epstein-Barr virus, Cytomegalovirus, Herpes simplex virus,Human herpesvirus 6, Varicella-zoster virus, Psittacosis (Chlamydophila psittaci), Q fever (Coxiella burnetii), Tularemia (Francisella tularensis), Histoplasma capsulatum, Cryptococcus neoformans neoformans and neoformans gattii, Coccidioides immitis, Cryptosporidium parvum, Cryptosporidium hominis, Mycobacteria tuberculosis and nontuberculous mycobacteria. - Suitably, the methods of the invention may be applied to a lower respiratory system infection caused by one or more of the following bacterial pathogens: Streptococcus pneumoniae, Haemophilus influenza, Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Legionella pneumonia, Moraxella catarrhalis, Mycoplasma pneumoniae, Chlamydophila psittaci, Coxiella burnetii, Francisella tularensis, Mycobacteria tuberculosis, and Chlamydophila (Chlamydia) pneumoniae.
- Suitably, the methods of the invention may be applied to a lower respiratory system infection caused by one or more of the following non-bacterial pathogens: Influenza virus A and B, Rhinovirus, Respiratory syncytial virus, Histoplasma capsulatum, Human metapneumovirus, Cryptococcus neoformans, Cryptococcus gatti, Coccidioides immitis,
Adenovirus 4 and 7, Parainfluenza virus, Coxsackievirus, Echovirus, Coronavirus (MERS-CoV, SARS), Hantavirus, Epstein-Barr virus, Cytomegalovirus, Herpes simplex virus,Human herpesvirus 6 and Varicella-zoster virus. - In one embodiment, the methods of the invention may be applied to a lower respiratory system infection caused by one or more of the following pathogens: Streptococcus pneumoniae; Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae; Legionella pneumonia, Escherichia coli, Haemophilus influenza, and Influenza virus A and B.
- As illustrated by the results presented in the examples section, the methods of the invention are able to distinguish between bacterial and non-bacterial lower respiratory system infections.
- Suitably, particular pathogens may be associated with particular lower respiratory system infections.
- Suitably, pneumonia may be caused by any of the following pathogens: Chlamydia pneumoniae, Escherichia coli, Haemophilus influenza, Klebsiella pneumoniae, Legionella pneumonia, Moraxella catarrhalis, Mycoplasma pneumoniae, Neisseria meningitides, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus agalactiae, and Streptococcus pneumoniae.
- In one embodiment, the methods of the invention may be applied to pneumonia in a subject. Suitably the pneumonia may be viral, bacterial, fungal or parasitic. In one embodiment, the methods of the invention may be applied to pneumonia caused by one or more of the following pathogens: Chlamydia pneumoniae, Escherichia coli, Haemophilus influenza, Klebsiella pneumoniae, Legionella pneumonia, Moraxella catarrhalis, Mycoplasma pneumoniae, Neisseria meningitides, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus agalactiae, and Streptococcus pneumoniae.
- Bacterial Infection Syndromes
- The term “bacterial infection syndrome” as used herein, refers to conditions caused by, or resulting from, the presence of a bacterial infection in a subject. Such conditions may be systemic or isolated to a particular tissue or organ of the body.
- Suitably a bacterial infection syndrome may be caused by a subject's response to a bacterial infection.
- Suitably, a bacterial infection syndrome may be caused by or associated with inflammation and/or injury of tissue(s) or organ(s)due to a bacterial infection.
- Suitably a bacterial infection syndrome may involve a particular tissue or organ, or may involve multiple tissues or organs.
- Suitably a bacterial infection syndrome involving a particular tissue or organ may be selected from: pneumonia (inflammation of the lower respiratory tract), pyelonephritis, urinary tract infection, gastroenteritis, cellulitis, impetigo, meningitis and osteomyelitis.
- Suitably a bacterial infection syndrome involving multiple tissues or organs may be selected from sepsis.
- Accordingly, the methods of the invention may be applied to a bacterial infection syndrome.
- In one embodiment, the methods of the invention may be applied to sepsis and/or bacterial gastroenteritis.
- By way of example, bacteria typically associated with sepsis in human subjects may include: Staphyloccocus species (e.g. Staphylococcus aureus), Streptococcus pyogenes, Escherichia coli, Pseudomonas aeruginosa, Klebsiella species, Streptococcus pneumonia and Neisseria meningitidis.
- In one embodiment, the methods of the invention may be applied to sepsis caused by a bacterium including: Staphyloccocus species (e.g. Staphylococcus aureus), Streptococcus pyogenes, Escherichia coli, Pseudomonas aeruginosa, Klebsiella species, Streptococcus pneumonia and Neisseria meningitidis.
- By way of example, bacteria typically associated with gastroenteritis in human subjects may include: Escherichia coli, Campylobacter jejuni, Salmonella enterica, Shigella dysenteriae.
- In one embodiment, the methods of the invention may be applied to bacterial gastroenteritis caused by a bacterium including: Escherichia coli, Campylobacter jejuni, Salmonella enterica, Shigella dysenteriae.
- The methods of the first, second and third aspects of the invention are methods for detecting an infection, detecting a bacterial infection and detecting a non-bacterial infection, respectively. In the context of the present disclosure, the term “detecting” is taken as meaning determining the presence of an infection, in particular a bacterial and/or a non-bacterial infection in a subject.
- Suitably, the methods of the invention may be used to detect lower respiratory system bacterial and/or non-bacterial infections, suitably which may be caused by any of the pathogens described in the relevant sections above. Suitably, the methods of the invention may be used to detect bacterial infection syndromes, suitably which may be caused by any of the pathogens described in the relevant section above.
- In one embodiment, the method of the invention may be used to detect an infection that is associated with symptoms in a subject. Alternatively, the methods may also be used to detect an infection that is essentially asymptomatic. Such asymptomatic infections may be infections that are at a very early stage.
- The inventors believe that the assessment, in the methods of the invention, of expression of genes associated with the subject's host response to bacterial infections to provide information regarding the presence of this condition confers notable advantages. Without wishing to be bound by any hypothesis, one such advantage may be that target molecules indicative of expression of such genes are found at detectable levels at earlier time points than are potential markers expressed by the bacteria associated with the infection. While levels of expression of bacterial genes may be difficult to detect, especially during the early stages of bacterial infections, the expression of host genes may be readily assessed. The greater abundance of such target molecules indicative of expression of host response genes not only allows such assessments to be made at an earlier time, but may also improve the accuracy of the assessment.
- Further, the methods of the invention, which involve assaying a sample representative of gene expression to obtain data indicative of the relative abundance of target molecules indicative of the expression of genes associated with the subject's host response to bacterial infections may be useful in determining the presence of a non-bacterial infection. This is due to the ability to rule out a bacterial infection based on the relative gene expression data. As mentioned above, ruling out a bacterial infection is advantageous as it prevents the subject from receiving unnecessary antibiotic treatment, reduces healthcare costs, and reduces risk of developing antibiotic resistance.
- As mentioned above, an infection may be a combined bacterial and non-bacterial infection. The inventors believe that the methods of first and second aspects of the invention may also be useful in detecting the presence of a bacterial infection in such a combined infection.
- The methods of the invention are methods are particularly suitable for use in detecting a lower respiratory system infection in a subject, whether it be a bacterial or non-bacterial infection.
- Once a lower respiratory system infection has been detected by a method of the invention an additional step may optionally be practiced, to confirm the detection. The additional step may comprise performing a further diagnostic test for a lower respiratory system infection. Such a further diagnostic test may be used to identify the bacterial pathogen present, if the infection is determined to be bacterial, or to provide information regarding the susceptibility of the bacterial pathogen to antimicrobial agents. Bacterial culture is an example of a test which may be used to identify the bacterial pathogen and/or its susceptibility to antimicrobial agents
- Examples of other such diagnostic tests that may be employed will be well known to those skilled in the art. Suitably the further diagnostic test may comprise a chest x-ray. Bacteria collected as part of the further diagnostic test may be investigated by culturing.
- The tenth aspect of the present invention allows the monitoring of the effectiveness of a treatment for an infection.
- Advantageously, the present inventors have discovered that the methods of detecting an infection of the invention still function to a high level of accuracy and specificity after a subject has begun receiving treatment for an infection. Therefore, the data indicative of the relative abundance of target molecules indicative of the expression of one or more gene pairs associated with the subject's host response can be measured before treatment and during treatment and after treatment.
- Suitably, data indicative of the relative abundance of target molecules indicative of the expression of one or more gene pairs associated with the subject's host response can be used to monitor the progression of an infection during treatment, and thereby the effectiveness of said treatment.
- Suitably the data indicative of the relative abundance of target molecules indicative of the expression of one or more gene pairs from the first sample and second sample is analysed.
- Suitably the data indicative of the relative abundance of target molecules indicative of the expression of one or more gene pairs from the first sample and second sample is analysed to calculate the relative abundance ratio of the one or more gene pair(s) in the first sample and second sample as explained elsewhere herein.
- Suitably comparing the data indicative of the relative abundance of the target molecules in the first sample and second sample comprises comparing the relative abundance ratio of the one or more gene pair(s) in the first sample and second sample.
- Suitably therefore a difference in the relative abundance of target molecules indicative of the expression of at least one gene pair between the first sample and second sample comprises a difference in the relative abundance ratio of the one or more gene pair(s) between the first sample and second sample.
- Suitably, a difference in the relative abundance ratio of the one or more gene pair(s) between the first sample and second sample indicates a change in respect of the progress of the infection.
- Suitably, the change in respect of the progress of the infection may be caused by the infection itself or may be in response to treatment. Suitably the change in respect of the progress of the infection may be an improvement or a worsening in the infection.
- In one embodiment, when monitoring a bacterial infection, an increase in the relative abundance of target molecules indicative of the expression of at least one gene pair between the first sample and second sample indicates a worsening in respect of the infection. In such an embodiment, an increase in the relative abundance of the target molecules indicative of the expression of at least one gene pair between the first sample and second sample indicates the treatment is ineffective. Suitably, in such an embodiment, an increase in the relative abundance ratio of the one or more gene pair(s) between the first sample and the second sample indicates a worsening in respect of the infection, and suitably indicates that the treatment is ineffective.
- Accordingly, in such an embodiment when monitoring a bacterial infection, a decrease in the relative abundance of the target molecules indicative of the expression of at least one gene pair between the first sample and second sample indicates an improvement in respect of the infection. In such an embodiment, a decrease in the relative abundance of the target molecules indicative of the expression of at least one gene pair between the first sample and second sample indicates the treatment is effective. Suitably, in such an embodiment, a decrease in the relative abundance ratio of the one or more gene pair(s) between the first sample and the second sample indicates an improvement in respect of the infection, and suitably indicates that the treatment is effective.
- Suitable measurement of the relative abundance of the target molecules indicative of the expression of at least one gene pair associated with the subject's host response is described elsewhere herein.
- Suitably, the first sample is taken at a first timepoint and the second sample is taken at a second timepoint. Suitably the second time point is after treatment is provided to the subject.
- Suitable treatments for bacterial and non-bacterial infections are described elsewhere herein. Suitably the relevant bacterial or non-bacterial treatment is provided to the subject in accordance with the infection that has been diagnosed.
- Suitably the second sample is taken up to 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 7 hours, 10 hours, 12 hours, 15 hours, 20 hours, 24 hours, 48 hours, or 72 hours, after treatment is provided to the subject.
- Suitably, the monitoring methods of the invention may make use of further samples at further timepoints (for example a third sample at a third timepoint, in addition to the first and second samples).
- The first, second (and any subsequent) timepoints may be separated by any time period during which it is wished to monitor the therapeutic effectiveness of a treatment.
- Suitably the time period may be hours, days, or weeks. Suitably the time period may be up to 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 7 hours, 10 hours, 12 hours, 15 hours, 20 hours, 24 hours, 48 hours, 72 hours, etc.
- The methods and medical uses are practiced in respect of a subject. The subject may be one requiring diagnosis or treatment for an infection, such as a bacterial or non-bacterial infection. In one embodiment, the subject is one requiring diagnosis or treatment for a lower respiratory tract infection or a bacterial infection syndrome.
- Suitably the subject may be a human subject. The subject may be a patient undergoing medical care, or an individual requesting medical care.
- In the methods of the first, second, fourth, fifth, eighth, ninth and tenth aspect of the invention, a suitable subject may be one believed to have a bacterial infection, such as a bacterial lower respiratory system infection or a bacterial infection syndrome. For example, a suitable subject may have symptoms consistent with a lower respiratory system infection bacterial infection, such as shortness of breath, weakness, fever and/or a cough. In such cases the methods of the invention may be of use in definitively detecting or diagnosing a bacterial infection to warrant treatment with an antibiotic agent. Alternatively, a suitable subject may lack some or all symptoms consistent with a lower respiratory system infection. As considered elsewhere in this specification, such a subject may be substantially asymptomatic.
- Alternatively, a suitable subject in the context of the methods of the present invention may be one believed to be at risk of developing an infection, or suffering from an infection, such as a bacterial or non-bacterial lower respiratory system infection. Such a subject may have been in contact with an individual suffering from a bacterial infection or non-bacterial infection, or may suffer from another disorder, which may render the subject at risk of developing a bacterial or non-bacterial infection.
- Alternatively still, in the method of the tenth aspect of the invention, a suitable subject may be one already diagnosed with an infection, such as a bacterial or non-bacterial infection. In such cases the methods of the invention may be of use in monitoring the effectiveness of a treatment provided to the subject.
- Suitably the subject is human. Suitably the subject is male or female. Suitably the subject is an adult or a child.
- A sample Representative of Gene Expression in a Subject
- The methods of the invention make use of samples that are representative of gene expression in the subject in respect of whom the method is being practiced. In particular, the methods of the invention use samples representative of expression of host response genes involved in a subject's response to bacterial infection. Methods of the invention may make use of any sample which contains target molecules that provide a representation of such gene expression in the subject in question.
- In suitable embodiment, the sample is a body fluid sample. Alternatively, suitable samples may include tissue samples, such as biopsies. In either case, a suitable sample (whether of a body fluid or tissue) may comprise biological cells from the subject that are involved in the host response to bacterial infection.
- A suitable body fluid sample may include: a blood sample (for example, a whole blood sample, a blood plasma sample, or a serum sample); or a cerebrospinal fluid (CSF) sample, or a synovial fluid sample.
- Blood samples are particularly suitable for use in the methods of the invention. The use of a blood sample (typically whole blood) is advantageous, since it is readily accessible. Additionally obtaining the sample is not associated with much less risk and patient discomfort than is the case for samples such as CSF, which is particularly advantageous in subjects with a suspected meningitis infection.
- Samples may be processed for the enrichment of target molecules. Suitable techniques for such enrichment may be determined with reference to the nature of the sample, and of the target molecule in question. Generally, examples of suitable techniques (such as techniques for the isolation of biological cells from a sample, and the preparation of the cells to yield gene transcripts) will be well known to those skilled in the art.
- Target molecules suitable for use in the method of the invention are any molecules which are representative of gene expression in the subject. Such target molecules may be representative of gene expression either directly or indirectly. By way of example, a suitable target molecule which is directly representative of gene expression may comprise an RNA transcript. A suitable target molecule which is indirectly representative of gene expression may comprise a protein encoded by the gene.
- It will be appreciated that the selection of the type of target molecule to be used in a method of the invention should be considered in connection with the nature of the sample representative of gene expression. In the case of a sample that contains host cells, a suitable target molecule may be either directly indicative of gene expression (such as an RNA transcript), or indirectly indicative of gene expression (such as a protein encoded by an expressed gene). In the case of a sample that is essentially acellular, the use of target molecules that are indirectly indicative of gene expression may be preferred, since such target molecules (an in particular protein examples of such target molecules) may be shed into the sample, even in the absence of biological cells.
- By the same token, the nature of the target molecule, and therefore the nature of the sample representative of gene expression, may be chosen in order to be consistent with use in a preferred assaying system.
- When practicing the methods of the invention, the sample is assayed to determine the relative abundance of the target molecules indicative of the gene expression of interest. Generally, techniques suitable for assaying gene expression in order to provide information regarding relative abundance will be known to the person skilled in the art. As set out above, a suitable assay technique may be chosen with reference to the nature of the sample and the target molecules.
- Merely by way of example, gene expression can be measured directly by techniques that allow the detection and quantification of RNA target molecules, such as RT-PCR, real-time PCR, Northern blot, RNA sequencing (RNA-seq) and RNA microarray.
- Gene expression can be measured indirectly, by techniques that allow the detection and quantification of protein target molecules, such as ELISA, radioimmunoassay, immunoprecipitation, Western blot and mass spectrometry. Other suitable techniques for assaying proteins may be known to the person skilled in the art.
- Suitably, gene expression of multiple genes or multiple pairs of genes, as is of interest in the present invention, may be measured simultaneously for example by a combinatorial assay. For example, the methods of the invention may be conducted by multiplex PCR. Alternatively, the methods of the invention may be conducted by multiple PCR tests.
- Advantageously, each of the genes/gene pairs for use in the methods of the invention are suitable for detection by PCR.
- The methods of the invention involve obtaining data indicative of the relative abundance of relevant target molecules indicative of gene expression. For the purposes of the present invention, such “data indicative of relative abundance” may be taken as encompassing any data that are capable of being used in determining the presence of an infection, such as a bacterial or non-bacterial infection, in a subject. In a suitable embodiment the data provide a quantitative indication of relative abundance of expression of members of gene pairs, for example with reference to relevant target molecules.
- To determine whether an infection, such as a bacterial or non-bacterial infection is present, the data indicative of relative abundance of target molecules may be analysed as further shown in the Examples section of this specification.
- The methods of the invention involve obtaining data indicative of the relative abundance of target molecules indicative of the expression of at least the gene pair DUSP1 and IFI27. These genes are first and second host response genes, respectively.
- The genes referred to herein are identified as follows:
-
TABLE 1 Gene Encodes ELANE neutrophil elastase IFI44L Interferon-induced protein 44-like CTSG Cathepsin G S1PR5 sphingosine-1- phosphate receptor 5GRK6 G protein-coupled receptor kinase 6TXLNA taxilin alpha DUSP1 dual specificity phosphatase 1APMAP adipocyte plasma membrane associated protein (formerly C20orf3) KMT2A lysine (K)-specific methyltransferase 2A HP1BP3 heterochromatin protein 1, binding protein 3SIGLEC1 sialic acid binding Ig- like lectin 1, sialoadhesinIFI27 interferon, alpha-inducible protein 27 NMT1 N- myristoyltransferase 1FLOT1 flotillin 1HUWE1 HECT, UBA and WWE domain containing 1, E3 ubiquitin protein ligase - In a suitable embodiment, the methods of the invention involve obtaining data indicative of the relative abundance of target molecules indicative of the expression of the gene pair DUSP1 and IF127 and optionally a further gene pair.
- Suitably, the further gene pair may be selected from any of the gene pairs set out in Table 2.
-
TABLE 2 First gene Second gene DUSP1 SIGLEC1 ELANE IFI27 DUSP1 IFI44L ELANE SIGLEC1 ELANE IFI44L CTSG IFI44L ELANE S1PR5 CTSG S1PR5 GRK6 TXLNA APMAP KMT2A DUSP1 HP1BP3 FLOT1 NMT1 APMAP HUWE1 ELANE SIGLEC1 DUSP1 NMT1 - More suitably, the further gene pair may be selected from the gene pairs set out in Table 3.
-
TABLE 3 First gene Second gene DUSP1 SIGLEC1 ELANE IFI27 DUSP1 IFI44L ELANE SIGLEC1 ELANE IFI44L - In a suitable embodiment methods of the invention may involve obtaining data indicative of the relative abundance of target molecules indicative of the expression of any one of the further gene pairs set out in Table 2, in addition to the gene pair DUSP1 and IFI27.
- In a suitable embodiment methods of the invention may involve obtaining data indicative of the relative abundance of target molecules indicative of the expression of at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, or all further gene pairs set out in Table 2, in addition to the gene pair DUSP1 and IFI27.
- In a suitable embodiment methods of the invention may involve obtaining data indicative of the relative abundance of target molecules indicative of the expression of any one of the further gene pairs set out in Table 3, in addition to the gene pair DUSP1 and IFI27.
- In a suitable embodiment methods of the invention may involve obtaining data indicative of the relative abundance of target molecules indicative of the expression of at least one, at least two, at least three, at least four, or all further gene pairs set out in Table 3, in addition to the gene pair DUSP1 and IFI27.
- Suitably, in an embodiment where data indicative of the relative abundance of target molecules indicative of the expression of one further gene pair is obtained, the further gene pair is ELANE and IF127.
- Suitably, in an embodiment where data indicative of the relative abundance of target molecules indicative of the expression of two further gene pairs is obtained, the further gene pairs are firstly ELANE and IFI27, and secondly DUSP1/SIGLEC1.
- Suitably, the methods of the invention may involve obtaining data indicative of the relative abundance of target molecules indicative of the expression of additional gene pairs beyond those set out in tables 2 or 3.
- The expression of the genes and gene pairs is investigated by assaying the sample for target molecules indicative of the expression of such host response genes, as referred to above.
- Suitably, in the methods of the invention, the step of determining comprises using the data indicative of the relative abundance of target molecules indicative of the expression of the one or more gene pair(s) to perform discriminant analysis.
- Suitably, discriminant analysis or discriminant function analysis is a method used to find a combination of features (for example expression levels for a combination of host response genes) that separates two classes (for example bacterial infections from non-bacterial infections). Suitably the combination of features may be the expression levels of one or more gene pair(s) under consideration. Suitably, the expression levels of the one or more gene pair(s) under consideration are determined from the data indicative of the relative abundance of target molecules indicative of the expression of the host response genes in each of the one or more gene pair(s).
- Consequently, the presence of a bacterial infection in the subject is determined to be present if the relative abundance of target molecules indicative of the expression of the one or more gene pair(s) under analysis satisfies a predetermined condition. By the same token, in a subject where the relative abundance of target molecules indicative of the expression of the one or more gene pair(s) under analysis don't satisfy the predetermined condition, the presence of a non-bacterial infection is determined.
- Suitable combinations of features i.e. gene pairs that may be employed in the methods of the invention are described herein, as are the means to determine the expression levels of one or more genes in each gene pair using the relative abundance of target molecules.
- Suitably the predetermined condition is satisfied if the calculated result of the discriminant analysis exceeds a predetermined threshold. An example of a suitable predetermined threshold that may be employed with reference to a discriminant analysis is described in the examples section.
- Suitably, the result of the discriminant function analysis provides the resulting relative abundance calculation which is suitable for use with the combination of gene pair(s) under consideration.
- Suitably the relative abundance calculation provides the relative abundance ratio of the one or more gene pair(s) under analysis.
- Suitably, the relative abundance ratio of the one or more gene pair(s) is compared to a predetermined threshold.
- In one embodiment, the step of determining comprises calculating the relative abundance ratio of the one or more gene pair(s) under consideration.
- Suitably, the relative abundance ratio of the one or more gene pair(s) is a ratio of the abundance of the first listed gene(s) relative to the abundance of the second listed gene(s) in the or each gene pair.
- Suitably, the presence of a bacterial infection in the subject is determined to be present if the abundance of the first listed gene(s) is increased relative to the abundance of the second listed gene(s).
- Suitably, the presence of a non-bacterial infection in the subject is determined to be present if the abundance of the second listed gene(s) is increased relative to the abundance of the first listed gene(s).
- In one embodiment, an increase in the abundance of DUSP1 relative to the abundance of IFI27 in a sample indicates the presence of a bacterial infection in a subject.
- In one embodiment, an increase in the abundance of IFI27 relative to the abundance of DUSP1 in a sample indicates the presence of a non-bacterial infection in a subject.
- In one embodiment, the step of determining comprises calculating the relative abundance ratio of the one or more gene pair(s) under consideration using a relative abundance calculation. Suitably the relative abundance calculation is determined using discriminant analysis as explained above. Suitably the relative abundance calculation is a linear equation.
- In one embodiment, the relative abundance ratio is calculated from a relative abundance calculation such as:
-
D=(1.03*log(1/Gene A+Gene B)/(1/Gene C+Gene D)) - In such an embodiment, the step of determining further comprises assessing whether the result of the relative abundance calculation is above a predetermined threshold. Suitably, the result of the calculation is the relative abundance ratio (D).
- Suitably, the presence of a bacterial infection in the subject is determined to be present if the result of the discriminant function satisfies a predetermined condition. Suitably, therefore, the presence of a bacterial infection in the subject is determined to be present if the relative abundance ratio satisfies a predetermined condition.
- Suitably, the presence of a non-bacterial infection in the subject is determined to be present if the result of the discriminant function does not satisfy a predetermined condition. Suitably, therefore, the presence of a non-bacterial infection in the subject is determined to be present the relative abundance ratio does not satisfy a predetermined condition.
- In one embodiment, the determining step comprises comparing the relative abundance ratio of the one or more gene pair(s) under consideration to a predetermined threshold value.
- In one embodiment, the determining step comprises determining whether the relative abundance ratio of the one or more gene pair(s) under consideration exceeds a predetermined threshold.
- Suitably the predetermined threshold is a relative abundance ratio of at least 1.18. Suitably, therefore the predetermined threshold is D>1.18.
- In one embodiment, the determining step comprises determining whether the relative abundance ratio of the one or more gene pair(s) under consideration exceeds 1.18.
- Suitably, the presence of a bacterial infection in the subject is determined to be present if the relative abundance ratio of the one or more gene pair(s) under consideration satisfies the predetermined condition. Suitably, the presence of a bacterial infection in the subject is determined to be present if one or more of the gene pair(s) under consideration has a relative abundance ratio of greater than 1.18.
- Suitably, the presence of a non-bacterial infection in the subject is determined to be present if relative abundance ratio of the one or more of gene pair(s) under consideration has a relative abundance ratio which does not satisfy a predetermined condition. Suitably, the presence of a non-bacterial infection in the subject is determined to be present if one or more of the gene pairs under consideration has a relative abundance ratio of less than 1.18.
- Suitably, the methods of the invention are able to determine the presence of an infection, and are able to distinguish between bacterial and non-bacterial infections, with at least 70%, at least 80%, at least 90%, at least 95% or 100% sensitivity.
- Suitably, the methods of the invention are able to determine the presence of an infection, and are able to distinguish between bacterial and non-bacterial infections, with at least 70%, at least 80%, at least 90%, at least 95% or 100% specificity.
- Suitably, the methods of the invention are able to determine the presence of an infection, and are able to distinguish between bacterial and non-bacterial infections, with at least 70%, at least 80%, at least 90%, at least 95% or 100% accuracy.
- In one embodiment, the methods of the invention are able to determine the presence of an infection, and are able to distinguish between bacterial and non-bacterial infections, with 100% sensitivity, 100% specificity and 100% accuracy.
- The examples provided herein advantageously demonstrate that testing for the relative abundance of transcripts of the gene pair DUSP1 and IFI27, provides 100% sensitivity, accuracy and specificity in determining the cause of an infection in patients. This level of sensitivity, accuracy and specificity is maintained when combined with testing for the relative abundance of transcripts of other gene pairs.
- The eighth aspect of the invention relates to a method of treating an infection in a subject, the method comprising:
-
- (a) assaying a sample representative of gene expression in the subject to obtain data indicative of the relative abundance of target molecules indicative of the expression of at least the gene pair DUSP1 and IFI27;
- (b) determining the presence of an infection in the subject in dependence on the data;
- (c) providing treatment for an infection when the determination indicates the presence of an infection.
- In a suitable embodiment, the infection may be a bacterial infection or a non-bacterial infection. This embodiment gives rise to additional aspects of the invention.
- In one aspect, the invention relates to a method of treating a bacterial infection in a subject, the method comprising:
-
- (a) assaying a sample representative of gene expression in the subject to obtain data indicative of the relative abundance of target molecules indicative of the expression of at least the gene pair DUSP1 and IFI27;
- (b) determining the presence of a bacterial infection in the subject in dependence on the data;
- (c) providing treatment for a bacterial infection when the determination indicates the presence of a bacterial infection.
- In another aspect, the invention relates to a method of treating a non-bacterial infection in a subject, the method comprising:
-
- (a) assaying a sample representative of gene expression in the subject to obtain data indicative of the relative abundance of target molecules indicative of the expression of at least the gene pair DUSP1 and IFI27;
- (b) determining the presence of a non-bacterial infection in the subject in dependence on the data;
- (c) providing treatment for a non-bacterial infection when the determination indicates the presence of a non-bacterial infection.
- In the context of the present disclosure, treatment of bacterial infections, such as bacterial lower respiratory system infections or bacterial meningitis, will generally involve the provision of antibacterial agents to a subject requiring such treatment. Suitable antibacterial agents include antibiotics such as those selected from the group consisting of: third generation cephalosporins (e.g. ceftriaxone, cefotaxime), ampicillin, penicillin G, meropenem, fluoroquinolone, trimethoprim-sulfamethoxazole, and chloamphenicol.
- Suitably an antibacterial agent for use in accordance with this aspect of the invention may be selected with reference to the nature of the bacteria giving rise to the bacterial infection, such as bacterial meningitis, to be treated.
- Thus, in the case of a bacterial infection with Streptococcus pneumoniae an antibacterial agent for use in accordance with this aspect of the invention may be selected from the group of: vancomycin plus a third-generation cephalosporin; ceftriaxone or cefotaxime; Meropenem (C-III), fluoroquinolonec (B-II).
- Thus, in the case of a bacterial infection with Neisseria meningitidis an antibacterial agent for use in accordance with this aspect of the invention may be selected from the group of: a third-generation cephalosporin; Ceftriaxone; Penicillin G, ampicillin, chloramphenicol, fluoroquinolone, aztreonam.
- Thus, in the case of a bacterial infection with Listeria monocytogenes an antibacterial agent for use in accordance with this aspect of the invention may be selected from the group of: Ampicillin (optionally with addition of an aminoglycoside) or penicillin G (optionally with addition of an aminoglycoside) Trimethoprim-sulfamethoxazole, meropenem (B-III).
- Thus, in the case of a bacterial infection with Streptococcus agalactiae an antibacterial agent for use in accordance with this aspect of the invention may be selected from the group of: Ampicillind or penicillin G (optionally with addition of an aminoglycoside) Third-generation cephalosporins (B-III).
- Thus, in the case of a bacterial infection with Haemophilus influenzae an antibacterial agent for use in accordance with this aspect of the invention may be selected from the group of: Third-generation cephalosporin, Ceftriaxone; (A-I) Chloramphenicol, cefepime (A-I), meropenem (A-I), fluoroquinolone.
- Thus, in the case of a bacterial infection with Escherichia coli an antibacterial agent for use in accordance with this aspect of the invention may be selected from the group of: Third-generation cephalosporin, ceftriaxone, (A-II) Cefepime, meropenem, aztreonam, fluoroquinolone, trimethoprim-sulfamethoxazole.
- Other suitable antibacterial agents will be known to those skilled in the art.
- In the context of the present disclosure, treatment of non-bacterial infections may involve treatment with an anti-viral, an anti-parasitic, an anti-protozoan, or an anti-fungal agent as appropriate to the infection.
- Merely by way of example, an anti-viral agent may be selected from the group consisting of an adamantane anti-viral agent, a chemokine receptor antagonist, an anti-viral interferon, an integrase strand transfer inhibitor, a neuraminidase inhibitor, a non-nucleoside reverse transcriptase inhibitor, a non-structural protein 5A (NS5A) inhibitor, a nucleoside reverse transcriptase inhibitor, a protease inhibitor and purine nucleoside. Other suitable anti-viral agents will be known to those skilled in the art.
- Merely by way of example, an anti-parasitic agent may be selected from the group consisting of Artemether, Albendazole, Amphotericin B, Eflornithine, Furazolidone, Ivermectin, Mebendazole, Melarsoprol, Metronidazole, Nifursemizone, Nitazoxanide, Ornidazole, Paromomycin sulphate, Pentamidine, Praziquantal, Pyrimethamine, Quinapyramine, Rifampicin, Tinidazole
- Merely by way of example an anti-fungal agent may be selected from the group consisting of Abafungin, Albaconazole, Anidulafungin, Bifonazole, Butoconazole, Caspofungin, Clotrimazole, Econazole, Efinaconazole, Epoxiconazole, Fenticonazole, Fluconazole, lsoconazole, Ketoconazole, Luliconazole, Micafungin, Miconazole, Omoconazole, Oxiconazole, Sertaconazole, Sulconazole, Tioconazole, Isavuconazole, Itraconazole, Posaconazoie, Propiconazole, Ravuconazole, Terconazole, Voriconazoie.
- The invention will now be further described with reference to the accompanying Experimental Results:
- We have undertaken a preliminary study in suspected lower respiratory tract infection (LRTI) patients admitted to hospital in the UK (unpublished data). Adult patients (n=17) were identified to have confirmed bacterial (bacterial culture positive), confirmed viral (pathogen specific viral PCR positive) lower respiratory tract infection (with consistent chest X-ray changes).
- Microarray data: Venous whole blood samples of 2.5 ml were taken and collected in RNA stabilising tubes (PAXgene) during hospital admission before treatment had started. Total RNA was extracted using Blood RNA Extraction kits (PAXgene) following the manufacturer instructions. Total RNA (500 ng per sample) was amplified and labelled using Low Input Quick Amp. Labelling kits (Agilent). Patient sample derived amplified RNA was labelled with Cyanine-3. Control human amplified RNA (Universal RNA) was labelled with Cyanine-5. Labelled RNA (200 ng) was hybridised to SurePrint G3 GE 8x60K (Design ID 030495) human-specific microarrays following the manufacturers' instructions (Agilent Technologies). Arrays were scanned using Agilent G2505C scanner (Agilent Technologies). Raw fluorescent intensity was measured and initial quality control assessment undertaken using Agilent Feature Extraction software (FE 10.5.1.1). Transcripts exhibiting a statistically significant difference in relative transcript abundance between proven bacterial cases and proven non-bacterial cases were identified based on the fold change and false detection rate (FDR) output from SAM 4.0. (http://wwwstat.stanford.edu/˜tibs/SAM). Gene-expression micro-array analysis of the patients' blood samples confirmed multiple genes exhibited differential abundance in the host response to bacterial compared to non-bacterial (in this case viral) respiratory infections (
FIG. 1 ). - Identifying top scoring pairs of markers: For our diagnostic, we aimed to identify pairs of markers (gene transcripts), where the first marker exhibited consistently higher expression than the 2nd marker in bacterial pneumonia cases. However in the comparator clinical group (viral infection), the expression ratio between the two markers changes, so that the 2nd marker, shows relatively consistent higher expression than the 1st marker. The “Top Scoring Pairs” of genes (TSPs) were identified using the open source program AUREA (Adapative Unified Relative Expression Analyser).
- Validating marker gene pairs on a PCR platform: The most accurate TSPs based on the microarray data were re-tested using quantitative RT-PCR to confirm diagnostic accuracy on a measurement platform routinely available in hospital laboratories. One reason for assessing marker performance is that shorter sequences are interrogated (typically 20mer) using PCR compared to arrays (>60mer). This can affect marker performance. TSPs were tested using our original patient samples, so we could compare performance. Pairs were tested via proprietary TaqMan primer/probe sets (one probe set against each transcript). Probes were exon-spanning and biased towards the 3′ end of mRNA. In pairs showing poor discrimination between groups, primers were re-designed based on array sequence. TSPs showing consistent performance by RT-PCR went forward.
- Developing a logical equation based on multiple TSPs improves diagnostic specificity: Specificity of individual TSPs can be variable. However, specificity for multiple pairs of genes when combined via a Boolean operand can be used to create a diagnostic with high sensitivity and specificity. This approach was applied to the six TSPs (composed of 5 discriminatory genes) based on the RT-PCR data. Interpretation of marker abundance within a logical rule enabled sensitivity to be increased from 17% to 100% (Table 4,
FIG. 2 ) - The resulting logical rule predicted a bacterial infection, if D>1.18, where D =1.49* (gene D/I) or alternatively D=1.67* (gene E/I) AND 1.49* (gene D/I) AND 1.035*(gene D/S) AND 1.68*(gene E/44) AND 1.29*(gene D/44) AND 1.25*(gene E/S).
- By way of further example, identification of the sample being as indicative of bacterial infection by relative transcript marker abundance ratio can also be arrived at using different equations. An example of such an alternative equation is as follows: if D [presence of bacterial infection]>1.1 where D=(1.03*log (1/Gene D)/(1/
Gene I OR 1/Gene 44 OR 1/Gene S)). - The markers correctly distinguished bacterial LRTI (n=13) caused by a range of bacteria: Streptococcus pneumoniae (n=7); Pseudomonas aeruginosa (n=3); Klebsiella pneumoniae (n=1); Legionella pneumonia (n=1); Escherichia coli (n=1); Haemophilus influenzea (n=1) (note: 1 patient had infection involving 2 bacterial pathogens) from viral LRTI (n=6). Transcript marker pair specificity (with sensitivity set at 100%) in the respiratory sample set (samples with confirmed diagnosis n=19) are shown in Table 4 and
FIG. 2 . -
TABLE 4 Specificity (%) at Sensitivity classifying of detecting bacterial bacterial from viral Transcript marker LRTI LRTI Accuracy pair (n = 13) (n = 6) (%) DUSP1/ IFI27 100% (13/13) 100 (6/6) 100 DUSP1/ SIGLEC1 100% (13/13) 83 (5/6) 95 ELANE/ IFI27 100% (13/13) 100 (6/6) 100 DUSP1/ IFI44L 100% (13/13) 17 (1/6) 74 ELANE/ SIGLEC1 100% (13/13) 17 (1/6) 74 ELANE/ IFI44L 100% (13/13) 17 (1/6) 74 Combined 100% (13/13) 100 (6/6) 100 - Accuracy of the markers among different patient cohorts: There is critical need for improved diagnostic tests in both high and lower middle income countries. However, a host test may be complicated by patients being infected with different bacteria or a different host response (e.g. secondary to a different genetic background). To begin to assess our gene pair markers (E/44-ELANE/IF144L; E/I-ELANE/IF127; D/44-DUSP1/IF144L; D/I-DUSP1/1F127; E/S-ELANE/SIGLEC1; D/S-DUSP1/SIGLEC1) in these circumstances we have examined marker performance using gene-expression data from other patient cohorts.
- Blood samples were collected from adult patients in Australia on consecutive days, for 3-5 days of follow-up. Patients were confirmed to have severe bacterial pneumonia (n=6) or severe influenza A H1N1 (n=4). Looking at samples taken on
day 1 of sampling only, 4 of the 5 transcript markers in combination were able to classify bacterial from viral infections with 100% sensitivity and 100% specificity (Table 5). -
TABLE 5 Specificity (%) at Sensitivity classifying of detecting bacterial bacterial from viral Transcript marker LRTI LRTI Accuracy pair (n = 6) (n = 6) (%) DUSP1/ IFI27 100% (6/6) 100 (4/4) 100 ELANE/ IFI27 100% (6/6) 100 (4/4) 100 DUSP1/ IFI44L 100% (6/6) 100 (4/4) 10 ELANE/ IFI44L 100% (6/6) 25 (1/4) 70 Combined 100% (6/6) 100 (6/6) 100 - Paediatric patients with bacterial infection syndromes were examined, focussing on pneumonia cases (n=12). The causative pathogens of pneumonia in this cohort included Streptococcus pneumonia (n=7) and Staphylococcus aureus (n=5). The data set also included viral influenza patients with fever (n=18). The 5 transcript markers distinguished bacterial pneumonia from viral infection with a sensitivity of 100% (12/12) and a specificity of 100% (18/18) as shown in table 6.
-
TABLE 6 Specificity at classifying Sensitivity bacterial of detecting LRTI bacterial from viral Transcript marker LRTI infection Accuracy pair (n = 12) (n = 18) (%) DUSP1/ IFI27 100% (12/12) 100 (18/18) 100 DUSP1/ SIGLEC1 100% (12/12) 55 (10/18) 91 ELANE/ IFI27 100% (12/12) 100 (18/18) 100 DUSP1/ IFI44L 100% (12/12) 67 (12/18) 93 ELANE/ SIGLEC1 100% (12/12) 78 (14/18) 96 ELANE/ IFI44L 100% (12/12) 78 (14/18) 96 Combined 100% (12/12) 100 (18/18) 100 - Additional investigation of the diagnostic accuracy of the 5 transcript markers in other data-sets, demonstrated a high sensitivity and specificity in several patient cohorts distinguishing a range of different bacterial infections from viral infections.
- Paediatric patients with a wider range of bacterial infection syndromes (n=58), including pneumonia, bacteraemia, urinary tract infection, pyelonephritis, abscess, meningitis and septic arthritis were examined. The causative pathogens for these infections included Streptococcus pneumonia (n=13), Staphylococcus aureus (n=16) and Escherichia coli (n=29). The transcript expression ratio for the different bacterial infection syndromes were again compared to influenza patients (n=18). The transcript markers distinguished bacterial from viral infection with a sensitivity of 100% (58/58) and a specificity of 89% (16/18), see Table 7.
-
TABLE 7 Sensitivity of detecting Specificity bacterial (%) at infection classifying syndromes bacterial (bacteremia, viral urinary infection at tract infection, sensitivity Transcript marker pyelonephritis; (n = 18 Accuracy pair n = 58) [influenza]) (%) DUSP1/ IFI27 100% (58/58) 0 (0/18) 77 DUSP1/ SIGLEC1 100% (58/58) 50 (9/18) 87 ELANE/ IFI27 100% (58/58) 61 (11/18) 92 DUSP1/ IFI44L 100% (58/58) 28 (5/18) 82 ELANE/ SIGLEC1 100% (58/58) 50 (9/18) 87 ELANE/ IFI44L 100% (58/58) 39 (7/18) 85 Combined 100% (58/58) 89 (16/18) 98 - Table 8 shows paediatric bacteraemia patients presenting to hospital with acute illness caused by Gram negative (E. coli) or Gram positive (S. aureus or S. pneumonia) bacteria present in the blood stream that were analysed. Diagnosis was established
-
Specificity (%) at classifying bacteremia Sensitivity from viral of detecting infection Transcript marker bacteremia (n = 18 Accuracy pair n = 20 [influenza]) (%) DUSP1/ IFI27 100% (20/20) 39 (7/18) 71 DUSP1/ SIGLEC1 100% (20/20) 50 (9/18) 76 ELANE/ IFI27 100% (20/20) 61 (11/18) 82 DUSP1/ IFI44L 100% (20/20) 28 (55/18) 66 ELANE/ SIGLEC1 100% (20/20) 50 (9/18) 76 ELANE/ IFI44L 100% (20/20) 39 (7/18) 71 Combined 100% (20/20) 89 (16/18) 95 - by bacterial blood culture. Adult or child viral patients (n=18) presenting to hospital with acute viral infection caused by influenza virus A were also analysed. Viral diagnosis was confirmed by direct fluorescent antigen or viral culture. The transcript markers distinguished bacteremia from viral infection with a sensitivity of 100% (20/20) and a specificity of 89% (16/18).
- Table 8:
- Table 9 shows results from children presented to hospital with clinical features of meningococcal (bacterial) sepsis (n=24). Neisseria meningitidis was detected in blood (or CSF) by culture or PCR. Patient gene expression was compared against healthy adults (n=21). The transcript markers distinguished bacterial sepsis from health with a sensitivity of 100% (24/24, specificity of 71% (15/21) and an accuracy of 87% (39/45).
-
TABLE 9 Specificity (%) at Sensitivity classifying (%) of sepsis from detecting healthy Transcript marker sepsis controls Accuracy pair n = 24 (n = 21) (%) DUSP1/ IFI27 100% (24/24) 5 (1/21) 56 DUSP1/ SIGLEC1 100% (24/24) 19 (4/21) 62 ELANE/ IFI27 100% (24/24) 5 (1/21) 56 DUSP1/ IFI44L 100% (24/24) 0 (0/21) 53 ELANE/ SIGLEC1 100% (24/24) 62 (13/21) 82 ELANE/ IFI44L 100% (24/24) 5 (1/21) 56 Combined 100% (24/24) 71 (15/21) 87 - Accuracy of the markers in patients with HIV co-infection: Given the host test is based on the body's response, the question arises as to whether the test will remain accurate among patients co-infected with HIV. This would be a particular concern in lower middle income countries (LMIC). To begin to address this, Malawian children presenting with invasive pneumococcal disease were examined. Half of the patients had HIV co-infection (n=6) and half did not (n=6), healthy patients (n=3) were also examined. The 5 transcript markers correctly distinguished all pneumococcal disease patients from healthy patients with a sensitivity of 100% (12/12) and specificity of 100% (3/3). This indicates the gene pairs can accurately identify bacterial infection syndromes among HIV+positive patients.
- Accuracy of the markers in distinguishing bacterial infection from parasitic infection: There is critical need for improved diagnostic tests in lower middle income countries. However, in this environment a host test may be complicated by patients being infected with parasites, such as malaria. To begin to assess six TSPs (E/44-ELANE/IFI44L; E/I-ELANE/IFI27; D/44-DUSP1/IFI44L; D/I-DUSP1/IFI27; E/S-ELANE/SIGLEC1; D/S-DUSP1/SIGLEC1) in these circumstances we have examined TSP performance using micro-array data from patients with proven bacterial infection and proven malaria.
- Gene expression values from microarray analysis of RNA from blood of adult patients with Plasmodium falciparum malaria (both uncomplicated and severe cases with complications of impaired consciousness, acidosis and/or anemia) were compared with the gene expression levels in patients with bacterial meningitis for the following transcript markers: DUSP1, IF127 and IF144L. In combination, these 3 transcript markers were able to classify cases of infections of bacterial meningitis from cases of P. falciparum malaria with a sensitivity of 100%, specificity of 93% and accuracy of 94% (Table 10)
-
TABLE 10 Specificity (%) at Sensitivity classifying of detecting bacterial bacterial meningitis Transcript meningitis from malaria Accuracy marker pair (n = 9) (n = 44) (%) DUSP1/ IFI27 100% (9/9) 75 (33/44) 80 DUSP1/ IFI44L 100% (9/9) 88 (39/44) 91 Combined 100% (9/9) 93 (41/44) 94 - Examining the impact of prior antibiotic exposure on test accuracy: Blood cultures are reported to be sterile within 2 and 4 hours of antibiotic exposure. Therefore pathogen directed diagnostics such as culture or PCR are less sensitive when patients have already received antibiotics (such as pre-hospital antibiotic treatment).
- To examine the impact of prior antibiotic exposure on the host genes, we assessed 6 transcript marker gene pairs (E/44-ELANE/IF144L; E/I-ELANE/IF127; D/44-DUSP1/IF144L; D/I-DUSP1/1F127; E/S-ELANE/SIGLEC1; D/S-DUSP1/SIGLEC1) in an extended set of bacterial (n=26) and mimic (n=150) patient samples. Tester was blinded to sample classification. The lower threshold of expression ratio for classifying a bacterial sample was set as −1.2 standard deviations below the mean expression ratio based on the bacterial samples previously measured. Unblinding, the test appeared to identify only 18/26 bacterial samples. However, on reviewing the clinical data, multiple bacterial samples were collected more than 5 days after initiation of intravenous antibiotics. There was a marked reduction in the transcript maker pairs expression ratio among patients exposed to over 5 days of antibiotics showing that the treatment was effective (
FIG. 3 ). - Analysing bacterial samples collected within 5 days, the test exhibited 100% (13/13) sensitivity and 90% (135/150) specificity. Distinguishing between proven bacterial and viral infection the test exhibited 100% (13/13) sensitivity and 98% (51/52) specificity. This observation indicates the test can still accurately and sensitively detect bacterial infection up to 5 days after initiation of antibiotics. The observation also indicates that the test of the invention can be used to monitor treatment and help confirm the infection is resolving after treatment has been provided to a subject.
Claims (16)
1-25. (canceled)
26. A method of detecting and optionally treating a bacterial infection in a subject, the method comprising:
(a) assaying a body fluid sample obtained from the subject to determine expression of at least the gene pair ELANE and IFI27 relative to each other; and
(b) determining the presence of the bacterial infection in the subject based on the presence of the expression of at least the gene pair ELANE and IFI27 relative to each other; and optionally,
(c) treating the subject having the bacterial infection by administering a therapeutically effective amount of an antibacterial agent.
27. The method of claim 26 , comprising treating the subject having the bacterial infection by administering a therapeutically effective amount of an antibacterial agent.
28. The method of claim 26 , wherein the bacterial infection is caused by a bacterium selected from the group consisting of: Streptococcus pneumoniae; Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae; Legionella pneumonia, Escherichia coli, and Haemophilus influenza.
29. The method of claim 26 , wherein the bacterial infection is a lower respiratory system infection and is caused by one or more pathogens selected from the group consisting of: Streptococcus pneumoniae, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus pyogenes, Pseudomonas aeruginosa, Bordatella pertussis, Neisseria meningitidis, Coxiella burnetiid, Corynebacterium, Klebsiella pneumoniae; Legionella pneumonia, Escherichia coli, Haemophilus influenza, Moraxella catarrhalis, Mycoplasma pneumoniae, Acinetobacter baumannii, Chlamydophila (Chlamydia) pneumoniae, Bordatella parapertussis, Neisseria gonorrhoeae, Campylobacter jejuni, Listeria monocytogenes, Mycobacteria tuberculosis and nontuberculous mycobacteria.
30. The method of claim 29 , wherein the lower respiratory system infection is pneumonia and is caused by one or more pathogens selected from the group consisting of: Chlamydia pneumoniae, Escherichia coli, Haemophilus influenza, Klebsiella pneumoniae, Legionella pneumonia, Moraxella catarrhalis, Mycoplasma pneumoniae, Neisseria meningitides, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus agalactiae, and Streptococcus pneumoniae.
31. The method of claim 26 , wherein the bacterial infection is a bacterial infection syndrome, selected from the group consisting of
i) sepsis caused by a bacterium selected from the group consisting of: Acinetobacter baumannii, Staphylococcus epidermidis, Staphylococcus saprophyticus, and Streptococcus pyogenes, and
ii) bacterial gastroenteritis.
32. The method of claim 26 , wherein the body fluid sample is selected from the group consisting of: a whole blood sample; a blood plasma sample; a serum sample; a cerebrospinal fluid (CSF) sample; and a synovial fluid sample.
33. The method of claim 26 , wherein step (a) comprises determining the expression of at least one further gene pair relative to each other.
34. The method of claim 33 , wherein the at least one further gene pair is selected from the group: DUSP1 and IFI27; DUSP1 and SIGLEC1; DUSP1 and IFI44L; ELANE and SIGLEC1; ELANE and IFI44L; CTSG and IFI44L; ELANE and S1PR5; CTSG and S1PR5; GRK6 and TXLNA; APMAP and KMT2A; DUSP1 and HP1BP3; FLOT1 and NMT1; APMAP and HUWE1; ELANE and SIGLEC1; and DUSP1 and NMT1.
35. The method of claim 33 , wherein the at least one further gene pair is selected from the group: DUSP1 and SIGLEC1; DUSP1 and IFI44L; ELANE and SIGLEC1; and ELANE and IFI44L.
36. The method of claim 26 , wherein step (b) comprises calculating the relative abundance ratio of the one or more gene pair(s).
37. The method of claim 36 , wherein step (b) further comprises comparing the relative abundance ratio of the one or more gene pair(s) to a predetermined threshold value.
38. The method of claim 37 , wherein step (b) further comprises determining whether the relative abundance ratio of the one or more gene pair(s) under consideration exceeds a predetermined threshold value, wherein the predetermined threshold value is 1.18.
39. The method of claim 26 , wherein assaying the body fluid sample comprises using a technique selected from the group consisting of RT-PCR, real-time PCR, Northern blot, RNA sequencing (RNA-seq) and RNA microarray.
40. The method of claim 26 , wherein assaying the body fluid sample comprises using a technique selected from the group consisting of enzyme-linked immunosorbent assay (ELISA), radioimmunoassay, immunoprecipitation, Western blot and mass spectrometry.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/111,996 US20240035097A1 (en) | 2018-04-12 | 2023-02-21 | Detection of bacterial infections |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1806052.5 | 2018-04-12 | ||
GBGB1806052.5A GB201806052D0 (en) | 2018-04-12 | 2018-04-12 | Detection of bacterial infections |
PCT/GB2019/051048 WO2019197833A1 (en) | 2018-04-12 | 2019-04-11 | Detection of bacterial infections |
US202017046268A | 2020-10-08 | 2020-10-08 | |
US18/111,996 US20240035097A1 (en) | 2018-04-12 | 2023-02-21 | Detection of bacterial infections |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2019/051048 Continuation WO2019197833A1 (en) | 2018-04-12 | 2019-04-11 | Detection of bacterial infections |
US17/046,268 Continuation US11608535B2 (en) | 2018-04-12 | 2019-04-11 | Detection of bacterial infections |
Publications (1)
Publication Number | Publication Date |
---|---|
US20240035097A1 true US20240035097A1 (en) | 2024-02-01 |
Family
ID=62203501
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/046,268 Active US11608535B2 (en) | 2018-04-12 | 2019-04-11 | Detection of bacterial infections |
US18/111,996 Pending US20240035097A1 (en) | 2018-04-12 | 2023-02-21 | Detection of bacterial infections |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/046,268 Active US11608535B2 (en) | 2018-04-12 | 2019-04-11 | Detection of bacterial infections |
Country Status (4)
Country | Link |
---|---|
US (2) | US11608535B2 (en) |
EP (1) | EP3775291A1 (en) |
GB (1) | GB201806052D0 (en) |
WO (1) | WO2019197833A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021205461A1 (en) * | 2020-04-08 | 2021-10-14 | Memed Diagnostics Ltd. | Rna markers for diagnosing infections |
CN115323074A (en) * | 2022-05-16 | 2022-11-11 | 北京爱普益生物科技有限公司 | Primer pair and kit for detecting respiratory tract pathogenic microorganisms and application of primer pair and kit |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7906278B2 (en) | 2001-02-28 | 2011-03-15 | Chondrogene, Inc. | Diagnosis of osteoarthritis by determination of asporin RNA levels |
FR2833968A1 (en) | 2001-12-20 | 2003-06-27 | Ct Medico Chirurgical De Tronq | Thematic biochip, useful e.g. for diagnosis, particularly of breast cancer, and treatment selection, comprises thematic probes and probes for interpretation |
US20040038201A1 (en) * | 2002-01-22 | 2004-02-26 | Whitehead Institute For Biomedical Research | Diagnostic and therapeutic applications for biomarkers of infection |
US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
RU2473555C2 (en) | 2006-12-19 | 2013-01-27 | ДжинГоу, Инк. | New method for functional analysis of body of experimental data and gene groups identified from said data |
WO2008109773A2 (en) | 2007-03-06 | 2008-09-12 | Cornell Research Foundation, Inc. | Chronic obstructive pulmonary disease susceptibility and related compositions and methods |
KR100985090B1 (en) | 2008-05-23 | 2010-10-04 | 한국과학기술연구원 | Biomarker for identification of exposure to chrysene and the method of identification using thereof |
CA2895133A1 (en) | 2012-12-13 | 2014-06-19 | Baylor Research Institute | Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis |
WO2015048098A1 (en) | 2013-09-24 | 2015-04-02 | Washington University | Diagnostic methods for infectious disease using endogenous gene expression |
WO2015103664A1 (en) * | 2014-01-09 | 2015-07-16 | Nepean Blue Montains Local Health District | Risk stratification in influenza |
GB201518597D0 (en) * | 2015-10-20 | 2015-12-02 | Univ Liverpool | Detection of bacterial infection |
WO2017149548A1 (en) | 2016-03-03 | 2017-09-08 | Memed Diagnostics Ltd. | Rna determinants for distinguishing between bacterial and viral infections |
KR102515555B1 (en) * | 2016-06-07 | 2023-03-28 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Methods for Diagnosing Bacterial and Viral Infections |
GB201612123D0 (en) * | 2016-07-12 | 2016-08-24 | Imp Innovations Ltd | Method |
-
2018
- 2018-04-12 GB GBGB1806052.5A patent/GB201806052D0/en not_active Ceased
-
2019
- 2019-04-11 US US17/046,268 patent/US11608535B2/en active Active
- 2019-04-11 EP EP19718827.9A patent/EP3775291A1/en active Pending
- 2019-04-11 WO PCT/GB2019/051048 patent/WO2019197833A1/en active Application Filing
-
2023
- 2023-02-21 US US18/111,996 patent/US20240035097A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210079483A1 (en) | 2021-03-18 |
EP3775291A1 (en) | 2021-02-17 |
GB201806052D0 (en) | 2018-05-30 |
WO2019197833A1 (en) | 2019-10-17 |
US11608535B2 (en) | 2023-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240035097A1 (en) | Detection of bacterial infections | |
EP3347488B1 (en) | Method for nucleic acid based diagnostic approaches including the determination of a deviant condition, especially a health condition and/or a pathogenic condition of a sample | |
CN107636172B (en) | Tool for diagnosing, predicting or monitoring pneumocystis pneumonia | |
Araos et al. | Microbial disruption indices to detect colonization with multidrug-resistant organisms | |
EP3325659A2 (en) | Genetic testing for predicting resistance of gram-negative proteus against antimicrobial agents | |
Yin et al. | Atypical pneumonia caused by Chlamydia psittaci during the COVID-19 pandemic | |
JP2023100971A (en) | Methods for predicting risk of developing pulmonary colonization/infection by pseudomonas aeruginosa | |
WO2019117257A1 (en) | Method for assisting in detection of breast cancer | |
EP3365462B1 (en) | Detection of bacterial infection | |
KR101996643B1 (en) | Marker for diagnosing Acinetobacter baumannii infection and uses thereof | |
JP2021129513A (en) | Mirna biomarkers for diagnosis of diffuse alveolar damage type drug-induced interstitial pneumonia | |
CN111455094A (en) | Composition, kit, application and method for detecting deep infection fungi | |
Diver et al. | Sputum microbiomic clustering in asthma and COPD reveals a Haemophilus‐predominant subgroup | |
Dellière et al. | Analysis of microbiota and mycobiota in fungal ball rhinosinusitis: specific interaction between aspergillus fumigatus and haemophilus influenza? J Fungi (Basel) 2021; 7: 550 | |
EP3967776A1 (en) | Use of p44 as marker for diagnosing anaplasmosis | |
Gündoğdu et al. | Rapid detection of difficult-to-culture bacterial pathogens using real-time nanopore sequencing | |
Wang et al. | Association of coagulase-negative staphylococci with orthopedic infections detected by in-house multiplex real-time PCR | |
Chioma et al. | Study of serum procalcitonin as a predictor of bacterial infection in patients with acute febrile illness | |
Abu Shabana et al. | Presepsin as a Diagnostic Marker in Central Line Associated Blood Stream Infection in Intensive Care Unit Patients | |
Jiang et al. | Clinical implications of trichomonads detected in bronchoalveolar fluid by metagenomic next-generation sequencing: a multicenter retrospective study | |
WO2024026440A1 (en) | Universal microbial identification | |
Burnham et al. | Structure and diversity of urinary cell-free DNA informative of host-pathogen interactions in human urinary tract infection | |
KR20230131324A (en) | Method of providing information for Sarcoptes scabiei diagnosis using nucleic acid-based lateral flow analysis | |
CN116656851A (en) | Biomarker and application thereof in diagnosis of chronic obstructive pulmonary disease | |
CN117957333A (en) | Use of a thin ring virus (TTV) as a marker to determine the risk of complications in patients admitted to a healthcare facility |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: THE UNIVERSITY OF LIVERPOOL, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GRIFFITHS, MICHAEL;REEL/FRAME:065936/0222 Effective date: 20231205 |